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INTRODUCTION 
Infectious atrophie rhinitis is a serious economic disease 
of swine. It has been estimated that from 5 to 25 percent of 
all market swine have lesions of turbinate atrophy. Bordetella 
bronchiseptica infection is considered to be a major cause 
although not the only cause of atrophic rhinitis epizootics. 
Even though Bordetella bronchiseptica isolates from several 
species of animals have been demonstrated to infect swine, the 
usual mode of transmission is for certain baby pigs to become 
infected within the first week of life by exposure to chroni­
cally infected dams. These infected young pigs then serve to 
infect other young pigs by aerosol exposure to the organism and 
thus establish an aerosol epizootic within a group of closely 
housed, susceptible young pigs. 
Naturally infected pigs 4 to 10 weeks of age have been 
shown by nasal swab culture to have the highest percentage of 
infected pigs as well as the greatest numbers of B. bronchisep­
tica organisms present. After the peak incidence of infection 
is reached, a gradual recovery occurs until in mature animals 
10 to 15 percent remain as infected carriers. These carriers 
serve as a reservoir of infection for the next generation of 
susceptible young pigs, thus perpetuating the cycle of 
infection. This gradual clearance of the respiratory tract 
infection usually proceeds so that the nasal cavity is the last 
area to be freed of the infection with the ethmoid turbinates 
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reputedly the last area of the nasal cavity to be freed of B, 
bronchiseptica, 
A procedure to monitor swine with B. bronchiseptica nasal 
infection has been developed. This procedure is based on the 
collection of nasal secretions on sterile swabs, with subse­
quent culturing of the material on a selective medium. Several 
years favorable experience with this detection system by 
research workers in this laboratory utilizing experimentally 
infected swine culminated in the initiation of a pilot, field 
control effort in October of 1970. This control program was an 
effort to eliminate Bordetella rhinitis from certain swine 
herds by detection and culling of infected breeding animals. 
The control program was based on the observation that Borde­
tella bronchiseptica can be recovered with reasonable accuracy 
from the nasal cavity of carrier swine by the culturing of 
nasal secretions and that the detection and elimination of such 
infected animals leaves a group of negative animals in the 
breeding herd that can be expected to produce Bordetella rhini­
tis free pigs. Two criteria for success of the nasal swab cul­
turing procedure were utilized: (1) production of swine free 
from clinical atrophic rhinitis and (2) production of swine 
culture-negative for B, bronchiseptica. Due to possible rein­
fection from external sources, the second criteria was consid­
ered to be the most demanding. 
The nasal swab culturing procedure is not applicable in 
all Bordetella rhinitis situations, is expensive, and if 
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successful produces a completely susceptible herd of swine. 
The necessity and desirability of an efficacious immunizing prod­
uct are evident. It has been demonstrated that naturally recov­
ered swine are extremely resistant to reinfection. This resis­
tance has been shown to last for several months and is not con­
sidered to be associated with significant levels of circulating, 
agglutinating antibody. In several other chronic infections of 
the mucous membranes, circulating antibodies have relatively 
little significance or are only indirectly related to resis­
tance to infection. Local immunity and mucoantibodies are of 
primary importance in such infections, particularly those which 
are confined to the mucous surfaces. In addition many patho­
genic organisms gain access to the host via the mucosal sur­
faces of the respiratory, gastrointestinal and urogenital 
tracts and via the mammary gland. It has been suggested that 
adequate immunization against these pathogens must include 
immune protection at this portal of entry. 
The present study was initiated toi (1) evaluate the 
nasal swab culture procedure as a method to control clinical 
Bordetella rhinitis epizootics, and (2) develop and evaluate 
B. bronchiseptica immunizing agents for the control of Borde­
tella rhinitis. 
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REVIEW OF THE LITERATURE 
This literature review covers three areas: 1, Bordetella 
bronchiseptica infection in swine and other animals. 2. Resis­
tance of swine to Bordetella bronchiseptica infection, and 3. 
The secretory immune system with emphasis on swine secretory 
immunoglobulins, immunoglobulin A, and respiratory tract local 
mucosal resistance and immunity. Previous reviews by Winsser 
(i960), Duncan (1965), Ross (I965)» Harris (1970) and Switzer 
(1970b) have dealt extensively with the history, pathology, 
bacteriology, animal pathogenicity, and infectivity of and 
resistance to Bordetella bronchiseptica. Since 1970 consider­
able additional information has been added to the literature 
concerning B. bronchiseptica and this review will primarily 
concentrate on these newly developed sources, 
Bordetella bronchiseptica Infection 
in Swine and Other Animals 
Bordetella rhinitis is a chronic disease of swine caused 
by infection of the nasal cavity with Bordetella bronchiseptica. 
This bacterium has been isolated from a wide variety of healthy 
as well as diseased animals and its main habitat is the respir­
atory tract, 
Bordetella bronchiseptica has been found to be widely dis­
tributed throughout the swine population (Phillips, 19^3; 
Switzer, 1956; Ray, 1959; i/Ecuyer, Roberts and Switzer, 196I; 
Dunne, Kradel and Doty, I96I; Cross and Claflin, 1962; Ross, 
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Switzer and Mare, 1963b; Pearce and Roe, 1966; Pashov, Kurbala 
and Sereda, 196?; Harris, Ross and Switzer, 1969; Ogata, 
Koshiraizu, Kang, Atobe, Yamamoto, Kino and Ikeda, 1970; Kang, 
Koshimizu and Ogata, 1971; Mermerski, 1973). Switzer (1956) 
reported that a bacterium subsequently identified as B. bronchi-
septica was capable of causing turbinate atrophy when inoculated 
intranasally as a pure culture into young pigs free from respir­
atory tract disease. This finding has been verified by many 
workers in several different laboratories (Cross and Claflin, 
1962; Ross, Duncan and Switzer, 1963a; Duncan and Ramsey, 1965; 
Duncan, Ross, Switzer and Ramsey, 1966b; Pearce and Roe, I966; 
Ross, Switzer and Duncan, I967; Pashov, Kurbala and Sereda, 
1967; Harris and Switzer, I968; Agar, 1969; Shimizu, Nakagawa, 
Shibata and Suzuki, 1971; Maeda, Tokuhisa and Shimizu, 1971; 
Kemeny, 1972 and 1973; Fetter, Switzer and Capen, 1973). Bor-
detella bronchiseptica is considered as an important cause of 
atrophic rhinitis epizootics in the United States (Harris and 
Switzer, 1972; Switzer and Farrington, 1972), Japan (Ogata et 
al.. I97O; Hasebe, 1971; Shimizu ejt , 1971), England (Done, 
1972; Betts, 1972), and Bulgaria (Mermerski, 1973). 
Akkermans, Ouwerkerk and Terpstra (I968) stated that anal­
ysis of smears from swine nasal cavities showed a close correla­
tion between the presence of B, bronchiseptica and the occur­
rence of "contagious sneezing" and turbinate atrophy, Schoss 
(1971) and Schoss, Dirks and Schimmelpfennig (1972) considers 
Pasteurella multocida to be the primary causal agent of 
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atrophic rhinitis in Northwestern Germany. Transmission trials 
were carried out with 18 strains of P. multocida isolated from 
pigs with atrophic rhinitis. Turbinate atrophy was demonstrated 
in 26 of 94 test animals necropsied at the age of 3 months. 
This work is subject to further evaluation however, as no nasal 
swab cultures for the isolation and identification of B. bron-
chiseptica nasal infections were taken or negative controls 
utilized. Typical atrophic rhinitis was produced in 3 to 7 day 
old piglets after intranasal instillation of cultures of P. mul­
tocida and/or B. bronchiseptica by Pashov et aj. (I967). 
Sterile filtrates of the cultures had no effect. MacKenzie 
(1969) does not regard atrophic rhinitis as an etiological 
entity since it has been associated with a variety of infec­
tious agents, e.g. B. bronchiseptica. P. multocida. Hemophilus 
suis, Corynebacterium pyogenes. Mycoplasma species, inclusion 
body rhinitis, cytopathic viruses and trichomonads. He stated 
other factors such as heredity, vitamin deficiency (A, D, or G), 
nutritional hyperparathyroidism, altered Ca and P levels, chem­
ical irritation, age of exposure, the use of chemotherapeutic 
agents, management and other environmental factors may influ­
ence the severity of the atrophic rhinitis in a given herd. 
Agar (1969) inoculated gnotobiotic pigs fed a ration defi­
cient in calcium (0.3# level) at 3 days of age with B, bron­
chiseptica and caused some degree of turbinate atrophy in 96 
percent of them. The atrophy was evident within 7 days of 
inoculation and at varying ages up to ^6 days. Osteodystrophia 
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fibrosa and pericytic osteolysis as a result of a dietary 
insufficiency of calcium did not contribute significantly to 
turbinate atrophy in the pigs in the age group 0 to 56 days. 
His results indicated that osteodystrophia fibrosa as a result 
of dietary insufficiency of calcium and turbinate atrophy 
induced by B. bronchiseptica occurred as two separate disease 
entities in this age group of gnotobiotic pigs. 
Shimizu et aj. (1971) in a work to determine if B. bronchi-
septica is the causative agent of atrophic rhinitis in hysterec­
tomy produced colostrum-deprived pigs caused typical turbinate 
atrophy in 100 percent of B. bronchiseptica inoculated pigs. 
They further noted the organisms decrease in incidence by 3 
months of age and that agglutinating antibodies appeared as 
early as 37 days post-challenge. A Bordetella bronchiseptica 
culture that was isolated from infectious nasal washings was 
used by Kemeny (1972) to produce turbinate atrophy in 36 per­
cent of intranasally inoculated pigs. The crude nasal washings 
caused turbinate atrophy in 81 percent and sedimented crude 
nasal washings caused turbinate atrophy in 100 percent of intra­
nasally inoculated pifçs. 
Fetter, Switzer and Capen (1973) caused turbinate atrophy 
in 100 percent of respiratory disease-free pigs inoculated with 
swine virulent (B strain) B. bronchiseptica in the first days 
of life. Turbinate atrophy was evident by 2-weeks post-
inoculation. 
The extent of atrophic rhinitis in the swine population is 
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difficult to assess. Dunn (1969) reported that the inspection 
of the nasal cavities of more than 1,600 swine slaughtered from 
1962 to 1969 indicated a prevalence of about 25 percent. 
Switzer (1970b) estimated that from 5 to 10 percent of slaugh­
tered swine from the United States swine producing areas have 
turbinate atrophy and that the growth rate may be retarded 
about 5 percent in the affected pigs as compared with healthy 
ones. He stated the economic loss caused by the occurrence of 
atrophic rhinitis consists of retarded growth, reduced feed 
efficiency and predisposition to other respiratory tract dis­
eases rather than a high mortality rate among the infected 
swine. Ross (1965) found an incidence of B. bronchiseptica 
in purebred and commercial herds ranging between 38 and 54 per­
cent while Harris et aJ.. (I969) found 25 percent of 102 Iowa 
swine herds culture-positive for this organism. In Japan, the 
first case of atrophic rhinitis was reported in I966, but it is 
assumed that it may have existed in Japan for quite some time 
prior to this date (Hasebe, 1971). Hasebe (1971) considered 
that the disease may have spread to about 20 percent of the 
Japanese swine population and it was estimated that the disease 
retarded growth rate by about 10 percent. Kang et (1971), 
in a field survey utilizing the agglutination test to determine 
the incidence of B. bronchiseptica and turbinate atrophy in 
400 4 to 8 week old swine from various districts of Japan, 
found antibodies against B. bronchiseptica in 5^.5 percent of 
the pigs. Comparison of 3 diagnostic methods, i.e. 
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serological (agglutination test), pathological (gross lesion 
examination) and bacteriological (B, bronchiseptica isolation) 
tests, revealed that the results were not always correlated, 
Pearce and Roe (196?) in studying 3 specific pathogen-
free (SPF) herds that contracted atrophic rhinitis, found an 
initial incidence of turbinate atrophy of ^5 percent which 
declined to an average of 35 percent. Their findings indicated 
atrophic rhinitis did not cause a significant difference in the 
maturity time from birth to 200 pounds of weight. 
Based on examination of the nasal cavities of 3»500 
Landrace market weight swine, Behrens (1971)» stated that the 
gross lesions (turbinate atrophy, septal distortion) associated 
with atrophic rhinitis were not pathognomonic. Sectioning of 
the nasal cavity at the level of the first premolar tooth was 
said to be of limited diagnostic value without a thorough 
understanding of the clinical and bacteriological picture. 
Bordetella bronchiseptica may cause severe damage to the nasal 
turbinate without causing significant damage to the dense bones 
of the wall of the nasal cavity (Duncan et a^., 1966b). There­
fore, inspection for twisted noses or nasal hemorrhage will 
enable diagnosis in only a small percentage of the actual cases 
of turbinate atrophy. 
Bordetella bronchiseptica can also cause primary pneumonia 
as well as atrophic rhinitis in swine (L'Ecuyer et , I96I; 
Duncan, Ramsey and Switzer, 1966a). No incidence figures are 
available to indicate the morbidity of B. bronchiseptica 
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pulmonary disease but Brown^ states B. bronchiseptica is a con­
sistant and relatively frequent bacterial pathogen which may be 
recovered in pure culture from pneumonic lesions of swine sub­
mitted to the Veterinary Diagnostic Laboratory, College of 
Veterinary Medicine, Iowa State University. 
The pigs nasal cavity may become infected with B, bronchi-
septica as early as 48 hours after birth (Harris and Switzer, 
1968). Switzer (1970a) states there are 3 general require­
ments necessary for B. bronchiseptica nasal infection to cause 
severe turbinate damage. These are: 1. The infection must 
occur at an early age, usually during the first 3 weeks of 
life. Swine several months of age or older may become infected, 
but they do not develop lesions. 2. The infection must be with 
a virulent strain. 3. The infection must be of adequate dura­
tion lasting at least 3 to 5 weeks. 
Once turbinate atrophy occurs the lesions may persist for 
long periods even though the infection may be cleared by ther­
apy or by the pigs natural defense mechanisms (Harris and 
Switzer, I969). Harris and Switzer (I969) state the recovery 
of infected swine usually proceeds so that the lung and trach­
eal infection is eliminated before the nasal infection is 
cleared. The ethmoid turbinates are reported to be the last 
area of the nasal cavity to be cleared from the infection (Ogata 
^Brown, L, N. 1973. Personal Communication. Veterinary 
Diagnostic Laboratory, Iowa State University, Ames. 
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et al.. 1970; Kemeny, 1973). Switzer and Farrington (1972) 
presented data on the natural clearing rate of B. bronchiseptica 
nasal infections that indicated up to 90 percent of pigs 4 to 
10 weeks of age may have infected nasal cavities. This infec­
tion gradually clears until at approximately 10 to 12 months of 
age only 10 to 15 percent of the animals remain as infected 
carriers. These pigs may serve as a reservoir of infection for 
their offspring, thus perpetuating the cycle of infection. 
Kang, Koshimizu and Ogata (1971) stated that B. bronchiseptica 
can be demonstrated from the nasal cavity in the early (1 to 3 
months after birth) or middle (4 to 5 months) stages of infec­
tion, but gradually decreased in the older animals. Turbinate 
atrophy was said to usually appear at 4 to 5 months of 
age and agglutinating antibodies against B. bronchiseptica were 
generally present at the end of the early stage or the begin­
ning of the middle stage of infection. 
Switzer and Farrington (1972) proposed that Bordete11a 
rhinitis spreads by 3 general methods: via nasal contact 
between infected sows and their progeny; via aerosol infection 
of young pigs, especially in farrowing houses or nursery envi­
ronments from other young pigs; and via exposure of susceptible 
swine to nonswine sources of infection. MacLean (1971) 
reported that infectious atrophic rhinitis was transmitted over 
a distance of 6 feet, but not over l6 feet and that the infec­
tive droplet size must therefore be between 10 and 80 microns. 
Various isolates of B. bronchiseptica are not of equal 
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virulence for swine. Some nonswine strains have been demon­
strated to cause typical atrophic rhinitis in swine, whereas 
other strains recovered from swine or other mammals may be of 
low virulence for pigs (Ross et a^. I967). One canine origin 
isolate was demonstrated to be regularly eliminated from the 
swine nasal cavity by the sixth to seventh week postinocula-
tion. Ross et (196?) further state that differences in 
pathogenicity of B. bronchiseptica isolates may account for 
differences in the severity of rhinitis and turbinate atrophy 
in different field cases where this agent is present. Agents 
such as Pasteurella multocida. Hemophilus spp. and inclusion 
body rhinitis virus may also play a significant role in the 
field disease. 
Swine experimentally infected with B. bronchiseptica were 
successfully freed of the infection by treatment with sulfa­
methazine or sulfaethoxypyridazine (SEZ) at the level of 100 
grams per ton of feed (Switzer, 1963). Since that time these 
sulfonamides have been incorporated with growth-promoting anti­
biotics and have enjoyed wide popularity as feed additives to 
swine rations. Harris et a^. (1969) conducted a survey that 
indicated 80 percent of the B. bronchiseptica isolates recov­
ered from infected herds were resistant to sulfonamides as 
determined by sensitivity disc assay. Woods et (1972) 
found a ration containing 100 grams chlortetracycline, 100 
grams sulfamethazine, and 50 grams of procaine penicillin per 
ton of feed effective in controlling B. bronchiseptica in the 
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nasal tract of pigs. Suhara et al. (1970) noted that in pigs 
infected with Bordetella rhinitis, the addition of tylosin-
sulfonamide feed additives reduced the severity of the nasal 
lesions and improved the weight gain, but did not eradicate 
B, bronchiseptica from the herd even when used in conjunction 
with pen disinfection and the parenteral and intranasal admin­
istration of antibiotics. 
In the course of work with experimentally induced B, bron-
chiseptica infections in swine it became necessary to develop 
a procedure to monitor nasal infections. This procedure was 
based on the collection of nasal secretions on sterile swabs 
with subsequent culturing on a selective medium (Ross, 1963). 
Akkermans (1972) concluded that the bacteriological investiga­
tion of the nasal flora in pigs is a useful method with which 
an impression of the occurrence of B. bronchiseptica and 
Pasteurella multocida on infected farms can be obtained. After 
several years experience with the nasal swab culture detection 
system in infected swine, it was decided the method had suffi­
cient merit to warrant its application to an initial experi­
mental field control effort (Switzer, 1970a), A pilot field 
control effort was therefore initiated in October, 1970 with 
the production of Bordetella rhinitis free pigs from B. bron-
chiseptica negative sows as the goal of the nasal swab control 
procedure. Switzer and Spear (1973) showed that 3^ B. bronchi-
septica culture-negative sows from 4 known Bordetella 
rhinitis herds weaned 317 pigs, all of which were culture-
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negative for B. bronchiseptica at 8 weeks of age. Switzer 
and Farrington (1972) found that the nasal swab culture control 
procedure was effective in elimination of clinical signs of 
atrophic rhinitis in l6 of 19 (85 percent) herds sampled. In 
21 initially culture-positive herds, 14 (67 percent) produced 
pigs that were free of B. bronohiseptica at weaning age. Nasal 
swab cultures from 6,970 mature breeding animals revealed 542 
(8 percent) culture-positive for Bordetella bronchiseptica. 
MacKenzie (I969) states that in the field respiratory 
disease epizootics in swine are usually caused by multiple eti­
ological factors. Pathological changes often have to be inter­
preted within the context of combined infections. Hereditary, 
environmental, nutritional or stress factors may be essential 
predisposing causes or other infective agents may act synergis-
tically to produce intensified respiratory tract lesions. 
Detailed histologic studies of atrophic rhinitis caused by 
B. bronchiseptica (Duncan and Ramsey, 1965; Duncan et al., 
1966b) have revealed that the organism localizes on the epithe­
lial surfaces of the respiratory tract. Under the influence of 
inflammation produced by B. bronchiseptica the normal porcine 
ciliated nasal epithelial cells became polyhedral in shape. 
The cilia were reduced in numbers and spaced further apart. 
Microscopic lesions consisted of hyperplasia and metaplasia of 
the epithelium, fibrosis and collagen formation in the lamina 
propria and resorption and replacement fibrosis in the bony 
core. The major part of the atrophy was accounted for by the 
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reduction in the size of the osseous core, Shimizu et al, (1971) 
reported that microscopic examination of experimentally pro­
duced turbinate atrophy caused by B. bronchiseptica revealed 
rarefaction of the osseous core and inflammatory changes of the 
nasal mucosa that were essentially the same as reported previ­
ously by Duncan et, al. (1966b), Fluorescent antibody staining 
indicated B, bronchiseptica among the cilia of the trachea and 
turbinates, but not in the underlying tissues. Conversely, 
Fetter, Switzer and Capen (1973) observed in the bone cells of 
the nasal turbinates of pigs experimentally infected with B. 
bronchiseptica. bacterial organisms with ultrastructural fea­
tures resembling those described for B, bronchiseptica in the 
immediate vicinity of degenerating bone cells and adjacent to 
mineralized bone matrix. Turbinate atrophy was clearly evident 
in the respiratory disease free pigs experimentally inoculated 
with B, bronchiseptica at two weeks post inoculation. The ven­
tral scroll of the ventral turbinate was most often affected 
first and most severely. 
Fetter and Capen (1971a and b) studied the ultrastructural 
lesions of bone cells in pigs with naturally occurring and 
experimentally produced atrophic rhinitis. The experimental 
atrophic rhinitis was produced with an inoculum of pooled mater­
ial from the nasal turbinates of pigs with the naturally occur­
ring disease. A variety of organisms were isolated from the 
inoculum including B. bronchiseptica and Pasteurella multocida. 
Fetter, Switzer and Capen (1973) evaluated ultrastructure 
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changes in the bone cells of the nasal turbinates of pigs exper 
imentally infected with B, bronchiseptica by intranasal 
inoculation. These were compared to control pigs of the same 
age and to pigs with experimentally transmitted (atrophic tur­
binate suspension inoculated) and naturally occurring atrophic 
rhinitis. Severe degenerative changes were observed in the 
osteoblasts and osteocytes in the diseased pigs. These altera­
tions progressed to atrophy and lysis of bone cells, reduction 
of osteoid formation and the degenerative cells were observed 
directly adjacent to the mineralized matrix of bone. Osteo­
clasts were similar in number and appearance to those in the 
control pigs. Fetter et al. (1973) concluded that the funda­
mental lesions in pigs with Bordetella rhinitis was reduced 
formation of the organic matrix by bone cells. Bone resorption 
in the vicinity of degenerating osteocytes and osteoblasts 
appeared to contribute to the overall loss of bone. They con­
cluded that there was no significant difference in the ultra-
structural lesions of bone cells in pigs with Bordetella rhini­
tis as compared to pigs with experimentally transmitted (atro­
phic turbinate suspension inoculated) or naturally occurring 
atrophic rhinitis. 
The nasopharynx, in common with many other mucous mem­
branes, is covered by a film of mucus kept in continuous motion 
by the cilia arising from its epithelium. Mucus transport by 
the ciliary escalator is a major defense mechanism for clear­
ance of airborne materials from the respiratory tract. This 
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action is brought about by coordinated ciliary beat, which is 
translated into effective clearance only in the presence of an 
intact respiratory tract mucosa and a mucus film of suitable 
properties, Sade et al. (1970) showed that the systemic role 
of mucus is highly specific and in a depleted tissue, the 
cause of failure of the mucociliary function is a decrease in 
the quantity of mucus. Mucus was stated to be an essential 
intermediary in the transport system and a minimal amount must 
be available to allow the cilia to perform their function, 
Kilburn (I967) states that the cohesiveness of hydrated mucin 
permits the mucus sheet to be dragged along above the surface 
of the ciliated epithelium. Its major functions may be to con­
trol transudation and to protect underlying cilia and cells 
from penetration by particles, viruses and bacteria. The cili­
ary mucous transport system's protective ability is reversibly 
decreased by cold, dehydration, trauma, oxidant gases and the 
action of bacterial and viral infection which probably destroy 
the epithelium. The mucosa can also be altered by inanition, 
vitamin A deficiency and hypothyroidism. Kilburn (I967) fur­
ther stated that air pollutants such as SOg, HgS, NH^ at lesser 
concentrations approaching those in environmental pollutiom may 
affect mucus transport by changing mucus or ciliary beating. 
Oncd protection har been destroyed or reduced from whatever 
cause, bacteria which could not penetrate the intact mucus 
layer or find a hospitable environment may become concentrated 
and colonization occurs. 
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To avoid exclusion and removal, Bordetella pertussis must 
be able to anchor itself to some fixed structure on the naso­
pharyngeal surface (Holt, 1972). It was shown that in whoop­
ing cough in children B. pertussis has a marked tendency to 
attach itself to the cilia of the nasopharynx. Holt (1972), 
using fibroblast cell cultures in a model system for the early 
stages of infection in natural whooping cough, found that B, 
bronchiseptica (strain B8760) was strongly adherent to MRC-5» 
Hela, Hep 2 and monkey kidney cell (MKC) cell lines in all 
suspending fluids. Electron microscopic study of intraventric­
ular infection of mice with B. pertussis has shown that the 
bacteria adhere to the microvilli between the ependymal cilia 
(Hopewell et a^., 1972). Harris (1970) demonstrated in vitro 
that B, bronchiseptica organisms attach to nasal epithelial 
cells and indicated this accounts for its high infectivity for 
the nasal mucosa of pigs. He further stated the eventual cil­
iary destruction by this organism probably reduces the effi­
ciency of the mucociliary system and allows for the establish­
ment of secondary respiratory pathogens (unattaching organisms) 
such as Pasteurella multocida. 
Duncan et al. (1966b) suggested that an organism capable 
of producing atrophic rhinitis such as B, bronchiseptica must 
release substances which diffuse into the tissue and elicit 
changes in the osseous core without causing a marked inflamma­
tory reaction. They proposed the endotoxin or a similar sub­
stance of B. bronchiseptica as a potential initiating agent. 
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Harris, Harris and Green (I968) subsequently demonstrated that 
B, bronchiseptica boivin extracts had a profound effect upon 
the energy conserving and transducing properties of isolated 
beef heart mitochondria. The extract was tentatively described 
as endotoxin-like, Fetter and Capen (1971b) stated that bac­
terial endotoxins released during a localized inflammatory 
reaction in the Schneiderian membrane of diseased pigs could 
result in degenerative changes of bone cells similar to those 
reported in their investigation, Harris, Switzer and Harris 
(1971) experimenting further with the effects of B. bronchisep­
tica boivin extracts on pig and beef heart mitochondria suggest 
that the boivin extract may contain the membrane-damaging com­
ponent responsible for infectious rhinitis. They proposed 
that a diffusable product such as that suggested by Duncan 
et al. (1966b) may be contained in the boivin extract and that 
the presence of these toxins near the osseous core of the nasal 
turbinate prevents the uptake of Ca** by the organic matrix of 
the turbinate by a mechanism similar to the effect of the 
extract upon mitochondria. The extract, however, was found to 
be heat labile and thus did not fit the classical characteri­
zation of endotoxins as heat stable lipopolysaccharides. No 
specific chemical constituent could be found as possessing 
activity against the mitochondrial energized processes. It was 
suggested that a possible mechanism for complete activity might 
be a complex composed of protein and lipopolysaccharide in a 
membranous configuration. 
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Bordetella bronchiseptica may be recovered from the 
respiratory tract of a wide variety of mammalian species 
(Winsser, 19^0; Switzer et 2^., I966; Switzer, 1970b), Of the 
various non-swine carriers of Bordetella bronchiseptica. the 
cat probably has the greatest potential for spread of the 
organism to susceptible young swine (Switzer and Farrington, 
1972). Fisk and Soave (1973) in a study of cats for carriers 
of B. bronchiseptica found that 10 percent of newly purchased 
random source cats had the organism in their upper respiratory 
tract and that at the end of a 3 week confinement period, 
the proportion of carriers had increased to 48 percent. They 
considered cats a potential source of this infection for sus­
ceptible laboratory animal species as well as other cats. 
Snyder et a2. (1973) isolate Bordetella bronchiseptica from 
the trachea and lungs of 10 cats that died from pneumonia. 
In experimental B. bronchiseptica infection in guinea 
pigs, Nakagawa et a^. (1971). found that infection rates were 
proportional to the number of organisms inoculated. Infection 
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occurred in few of the animals receiving 10 organisms, but 
occurred in the majority of the animals receiving 10^ organ­
isms and in all of the animals inoculated with 10^ organisms. 
Subcultures on MacConkey's agar rapidly lowered the infectivity 
of the organisms for guinea pigs. 
Mayer (1971) and Oldenburg et (1972) have reported 
on B. bronchiseptica infection in large rabbit farms. Borde-
tella bronchiseptica was found to cause bronchopneumonia 
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in both germfree and conventional rats by Burek et aJ., (1972) 
and Farrington (1973) found B. bronchiseptica in 4 of 11 short-
tailed shrews. loakiinidis et (1970) reported a B. bronchi­
septica epizootic on a large chinchilla ranch; Graves (1970) 
considered B. bronchiseptica as the cause of a pneumonia epizo­
otic in a monkey colony containing 4 different species; 
Saxegaard et al. (1971) found B. bronchiseptica to be the etio­
logical agent in a case of equine bronchopneumonia; and Hall 
et al. (1971) isolated B. bronchiseptica from the lung of a 
beached pacific pilot whale. A case of cross-infection of B, 
bronchiseptica from infected pigs to the noninfected controls 
within an isolation unit was attributed to a heavy infestation 
of Pharaoh's ants by Beatson (1972) 
Nakase (1957 a,b,c,d) made an extensive examination of the 
antigenic structure, phase variation, biological properties and 
serological relationships of B. bronchiseptica. He described a 
capsular thermolabile L antigen, flagellar thermolabile H anti­
gen, surface slightly-thermostabile S antigen and somatic 
thermostabile 01, 05 and 07 antigens. Bordetella bronchiseptica 
was divided into 3 smooth phases and 1 rough phase and 
was said to be an extremely unstable organism with easy varia­
tion from phase I to phase IV by cultivation. Phase I organ­
isms were considered to be pathogenic. Biological differences 
existed between phase I and III in regard to acid agglutination, 
hemagglutination, toxicity, virulence and protective potency to 
mice. Dog, guinea pig and human B. bronchiseptica isolates 
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showed antigenic variation. 
Mason (1971) reported the growth of B. bronchiseptica cul­
tures in a graded series of glycine concentration. Gradual 
inhibition of growth occurred in glycine concentration up to 1 
percent while higher concentrations greatly inhibited growth 
and caused some autolysis. Sixteen hour cultures in 1 percent 
glycine were almost completely converted to aberrant forms and 
spheroplasts. Karaivanov e^ al. (1972) demonstrated the inhib­
itory effect of a B. bronchiseptica strain on growth of 
Pasteurella multocida organisms. The inhibitory factor was 
demonstrable only on solid media. 
Terakado et aJ.. (1973) demonstrated that R factors carry­
ing sulfadimethoxine-streptomycin-aminobenzyl penicillin 
resistance was present in strains of B. bronchiseptica isolated 
from pigs. All strains could transfer their drug resistance 
as 1 unit to a sensitive strain of Escherichia coli as well 
as to B. bronchiseptica by mixed cultivation. Thi increased 
prevalence of R factors in bacteria of animal origin was said 
to be a serious problem for animal hygiene and public health. 
Azechi et al. (1973) tested 6l strains of B. bronchiseptica 
isolated from swine for sensitivity to 52 antibacterial drugs 
by means of a plate dilution method. Thirty-nine isolates 
were from pigs showing clinical signs of atrophic rhinitis. 
Of the isolates tested 11.5 percent were resistant to sulfa 
drugs and showed a cross resistance to aminobenzyl penicillin 
and streptomycin. Wilkins and Helland (1973) found I7 isolates 
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of B. bronchiseptica from dogs with tracheobronchitis resistant 
to lincomycin, penicillin, streptomycin, nitrofurantoin and 
tylosin as determined by sensitivity disc testing. The activ­
ity of selected antibacterial agents against a swine isolate of 
B. bronchiseptica was evaluated in a 7-day-old embryonating 
hens egg system by Shirk and Kemp (I967). Single doses of the 
desired amount of drug were injected into the allantoic cavity 
prior to infection of the yolk sac with B, bronchiseptica. 
Survival data indicated the most effective drug was sulfaethox-
ypyridazine, followed by sulfathiazole and sulfaquinoxaline. 
Blood chemistry changes in swine from 1 to 12 weeks of age 
infected with Bordetella bronchiseptica intranasally were exam­
ined by Baetz et a^. (1974) to determine if they might be of 
diagnostic value. Lactic dehydrogenase (LDH) activity, lactic 
acid and total protein concentrations were found to be signif­
icantly higher in the infected piglets than in controls at a 
few time periods early in the infection. However, it was 
stated the minor changes in blood chemistries caused by B. bron­
chiseptica superimposed on the dynamic changes in blood chem­
istry taking place in the rapidly growing piglet make it 
impractical to use blood chemistry measurements for diagnostic 
purposes in this disease. 
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Resistance of Swine to 
Bordetella bronchiseptica Infection 
Harris (1970) has extensively reviewed the resistance of 
various animals to Bordetella bronchiseptica and Bordetella 
pertussis; therefore, only those selected references which have 
relevance to Bordetella bronchiseptica resistance in swine will 
be included in this discussion, 
Bordetella bronchiseptica and B. pertussis are antigenic-
ally related (Blair et aA,, 1970). Andersen (1953) demon­
strated that B. bronchiseptica and B. pertussis have similar 
0-antigens, a similar hemorrhagic toxin and common as well as 
species-specific K-antigens. The mechanism of immunity follow­
ing B. pertussis infection or immunization has not been clearly 
defined (Aftandelians and Connor, 1973) and no satisfactory 
purification of the protective antigen from B, pertussis has 
yet been accomplished (Sato and Nagase, 1967; Ross and Munoz, 
1971). 
Munoz (1963) listed the following antigens or substances 
to be present in B. pertussis 1 agglutinogen, heat-labile toxin, 
heat-stable toxin (endotoxin), hemagglutinin, histamine-
sensitizing factor and protective antigen. The agglutinogen 
and hemagglutinin were thought to be cell surface capsular 
antigens while protective antigen, histamine-sensitizing factor 
and endotoxin were associated with the cell wall. Heat-labile 
toxin was considered to be of protoplasmic origin. Ross and 
Munoz (1971) considered it well established that agglutinogens, 
25 
endotoxin, heat-labile toxin and hemagglutinins were not 
involved in the active immunization of mice intracranially chal­
lenged with virulent B, pertussis. They further reported hista-
mine-sensitizing factor and protective antigen were found in 
the same fraction and that their physical and chemical proper­
ties were similar if not identical. 
Standfast (1967) agreed that most of the protective activ­
ity was found in the cell wall, but that it was still open to 
question whether the protective antigen was identical with the 
histamine-sensitizing factor. Milleck and Ocklitz (1972) 
reported that B. pertussis spheroplast cell walls gave better 
protection than the corresponding intact spheroplasts and 
purified K-agglutinogen was found to lack protective activity 
by Nakase and Kasuga (1971). 
Ackers and Dolby (1972) investigated a circulating comple­
ment mediated bactericidal antibody appearing after an injec­
tion of vaccine to determine if it might be responsible for 
the protection of immunized mice. They concluded that the 
bactericidal antibody (bactericidin) was not necessary for the 
protection of mice. Complement-dependent bactericidal anti­
bodies were detected in the sera of 24 persons with bacterio-
logically confirmed pertussis and the development of humoral 
bactericidal antibody during pertussis was considered to indi­
cate a role in immunity although a mechanism was not demon­
strated (Aftandelians and Connor, 1973). It was postulated 
that the protective antibody reacted with the invading 
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organism on the surface of the respiratory epithelial cells in 
the case of intranasal challenge and prevented extension of 
infection by limiting replication or adherence or by other 
means. 
Holt (1972) observed that the incubation of live B, pertus­
sis and B, bronchiseptica in the presence of certain cell 
cultures resulted in adhesion of the bacteria onto the cell 
surfaces. This adhesiveness was lost if the bacteria were 
given prior treatment with immune antisera. A similar mechan­
ism was believed to operate on the surface of the respiratory 
epithelium by the action of either locally produced (IgA) or 
serum (IgG) antibody (Aftandelians and Connor, 1973). Holt 
(1972) found it probable, in accord with Tomasi and Bienenstock 
(1968) and Tomasi (1970), that B. pertussis reinfection, e.g. 
after intranasal vaccination, is prevented by locally produced 
IgA antibody which prevents bacterial adhesion to the 
epithelium. This antiadhesive mechanism was said to be greatly 
improved by the continuous flow of mucus over the epithelial 
surface, Harris (1970) also demonstrated hi vitro that swine 
nasal epithelial cells attached to B, bronchiseptica organisms 
and he postulated that such an inhibition of attachment to 
nasal and tracheal epithelial cells may be a mechanism by which 
respiratory tract resistance could be explained. Holt (1972) 
further stated that the current practice of vaccinating infants 
subcutaneously with B. pertussis vaccines may induce not a pro­
phylactic but a therapeutic immunity and that to confer true 
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prophylaxis against pertussis may require the addition of 
aerosol vaccination to the present immunization program, 
Kang, Koshimizu and Ogata (I97O) used live B. bronchisep-
tica grown in broth as an agglutinogen for use with immune 
serum in order to develop a serological test for the diagnosis 
of atrophic rhinitis in naturally infected pigs. A tube agglu­
tination test was developed and great care was used to select 
the strain used in the agglutination reaction. The first 
appearance of agglutinating antibody in the naturally infected 
pigs was at about 20 weeks of age, Kang, Koshimuzu and Ogata 
(1971) subsequently used this agglutination test to carry out 
a field survey to determine the incidence of B. bronchiseptica 
and turbinate atrophy in 400 pigs 1 to 8 months of age 
from various districts of Japan. Lesions were found in 91,4 
percent of the serologically positive pigs while pigs evidenc­
ing pathological lesions showed a 77 percent positive reaction 
in the agglutination test. They concluded that a serological 
test was available for the diagnosis of Bordetella rhinitis in 
swine. Ogata, Kodama and Koshimizu (1973) reported on the 
successful use of formalin-killed phase I B. bronchiseptica as 
antigens in a tube agglutination test for the diagnosis of B, 
bronchiseptica in swine. 
Harris (1970) and Harris and Switzer (1972) reported the 
development of a particulate antigen settling test (PAST) for 
the detection of antibody against B. bronchiseptica infection 
in swine, Harris (1970) stated that nasal resistance to 
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B, bronchiseptica infection did not appear to be correlated 
with serum antibody as determined by the particulate antigen 
settling test. 
Ross ejt a^. (1967) reported that sera of experimentally 
infected pigs may contain low levels of agglutins 4 weeks 
after exposure while Shimizu et (1971) demonstrated an 
increase of agglutinins in sera from hysterectomy derived, 
colostrum deprived pigs after B, bronchiseptica challenge, 
Kemeny (1973) found that B. bronchiseptica multiplied rapidly 
on the mucosal surface of the respiratory tract of young pigs, 
that the infection induced the formation of agglutinins and 
that turbinate atrophy occurred in 65 percent of the experi­
mentally exposed pigs. It was stated that the demonstration 
of a rise in agglutinating antibody titer in at least 2 prop­
erly timed serum samples may help confirm B. bronchiseptica 
infection in a swine herd where nasal swab culturing was 
unsuccessful. 
Kemeny and Amtower (1973) used an agglutination test 
employing killed B. bronchiseptica to detect naturally-occur­
ring antibody against this organism in the sera of 4^1 pigs 
1 month to over J6 months of age. It was stated that nasal 
swab cultures did not reliably detect the carrier state of 
subclinically infected pigs and that detection of agglutinat­
ing antibody against B. bronchiseptica may be useful for diag­
nosing infection in swine herds. 
Resistance to B. bronchiseptica infection in swine may be 
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due to the action of immunizing agents (acquired resistance) or 
to the pigs' own inherent immune mechanisms (natural 
resistance), Harris and Switzer (19^9) reported that swine 
freed from virulent B, bronchiseptica infection with sulfona­
mide treatment or by natural clearance of a low-virulence 
strain (canine origin D-1 strain) of B. bronchiseptica were 
extremely resistant to reinfection. This natural resistance 
lasted for at least several months and was not found to be 
associated with the presence of demonstrable bactericidal sub­
stances or with significant levels of circulating agglutinating 
antibody (Harris and Switzer, 1969; Harris, 1970). 
Tomasi and Bienenstock (I968) stated that in certain in­
fections, circulating antibody has relatively little signifi­
cance or is only indirectly related to resistance to infection. 
Local immunity and mucoantibodies may be of primary importance 
in the defense against some infections especially those which 
are noninvasive and confined to the mucous surfaces, 
Bienenstock and Perey (1972) noted that local presentation of 
antigen to the respiratory tract appears to preferentially 
induce local antibodies (IgA) which were better correlated with 
subsequent resistance to reinfection than were circulating 
antibodies stimulated by the parenteral administration of the 
same antigen. ^ 
Holt (1972) observed that it was probable that 2 immune 
systems were of importance in whooping cough 1 (1) A true pro­
phylactic immunity in which locally produced IgA secretory 
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immunoglobulin prevented the adhesion of the organism to the 
mucous membrane; and (2) A therapeutic system, involving poly­
morphs and an opsonin which after the development of inflamma­
tion acted at the surface of the membrane and eliminated the 
infection. 
Rabbits (Ferry and Hoskins, 1920), rats (Wickert et al., 
1958)» mice (Winsser, 19^0) and guinea pigs (Nikkels and 
Mullink, 1971) have been protected against B. bronchiseptica 
pneumonia by the use of B. bronchiseptica vaccines, Yoda e;t 
al. (1972) demonstrated the development of resistance to rein­
fection in guinea pigs recovered from B. bronchiseptica 
pneumonia. It was previously shown that no differences of 
susceptibility to intranasal infection by the organism existed 
among individuals and that the development of infection 
depended only upon the number of organisms inoculated 
(Nakagawa et , 1971). The intranasally infected guinea 
pigs usually recovered within 20 weeks and most of the recov­
ered animals were highly resistant for as long as 40 weeks or 
more after recovery from the natural infection. Graves and 
Shah (1972) stated that the development of a B. bronchiseptica 
vaccine would be advantageous for the control of B. bronchi­
septica pneumonia epizootics in laboratory monkey colonies. 
Kendrick et al. (1939) first reported on the successful 
immunization of humans against whooping cough by use of B. 
pertussis vaccines. It is generally accepted that the degree 
of protection against whooping cough is not correlated with 
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the serum agglutinin titer associated with pertussis immuniza­
tion (Medical Research Council, 1959). Holt (1972) used a B. 
pertussis aerosol vaccine in an attempt to induce local immun­
ity in a Taiwan monkey. Both humoral and locally produced 
secretory antibody were produced, but the results were in gen­
eral unsatisfactory. 
Daughtery (19^1) reported that swine with atrophic rhini­
tis showed a clinical improvement when administered a canine 
mixed bacterin containing B, bronchiseptica. Phillips (1944) 
and Ray (1959) stated that a bacterin containing B, bronchisep-
tica prevented pneumonia caused by this organism in swine. 
Harris and Switzer (1969), however, made the first clear demon­
stration of the induction of resistance in swine to B. bronchi-
septica infection. Harris and Switzer (1972) using a sonicated 
vaccine with adjuvant, prepared by sonically disrupting B. 
bronchiseptica strain D-1 and a commercially purchased pertus­
sis vaccine demonstrated accelerated nasal clearance of B. 
bronchiseptica nasal infections. They reported high levels of 
circulating, agglutinating antibodies were stimulated by these 
vaccines. They had previously demonstrated (Harris and 
Switzer, 19^9) that a whole-cell vaccine (strain B) without 
adjuvant did not induce nasal resistance against virulent B. 
bronchiseptica challenge. The accelerated recovery from infec­
tion was not manifested by a complete refractiveness against 
the challenge organisms since 40 to 60 days were required for 
the clearance of the challenge organisms. 
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Matsuura^ concluded that immunization with attenuated B, 
bronchiseptica may be effective to prevent infection with B. 
bronchiseptica to some extent and to significantly inhibit 
development of atrophic rhinitis in swine. Bordetella bronchi­
septica was detected in 4-9 percent of the vaccinated pigs and 
in 77 percent of the unvaccinated controls. Gross lesions of 
atrophic rhinitis were found in 7 percent of the vaccinated 
pigs and 59 percent of the unvaccinated pigs. Forty-five 
Q 
X 10^ organisms were administered subcutaneously in 2 doses, 
2 weeks apart. 
2 Kawahira parenterally immunized pigs with inactivated B. 
Q 
bronchiseptica using a total dosage of 225 X 10 organisms 
administered in 3 doses beginning the third day after birth. 
Bordetella bronchiseptica was not cultured from the nasal cav­
ity of these immunized pigs on or after 18 to 26 days post 
challenge while all control pigs yielded the organism continu­
ously to 109 days post-challenge. It was concluded that B. 
bronchiseptica immunization was effective, even in 3-day-
old pigs, in preventing B. bronchiseptica nasal infections. 
Matsuura, S. 1972. The preventive effect of attenuated 
B. bronchiseptica on atrophic rhinitis in swine. Unpublished 
data. Western Regional Animal Hygine Service Station, Ibaragi 
Prefecture, Japan. 
2 Kawahira, M. 1972. An immunological study with atten­
uated B, bronchiseptica in swine. Unpublished data. Kitasato 
Biological Institute, Japan. 
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Ohmura^, however, parenterally immunized pigs of varying ages 
with 2 doses of an inactivated B, bronchiseptica vaccine 
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using a total dosage of 105 X 10 organisms and found the com­
parative ratios of B, bronchiseptica isolation in the vacci­
nated pigs versus the unvaccinated pigs to be as follows: 14^ 
vs. 30% 6 weeks post - vaccination, 20^ vs. 44^ 11 weeks after 
vaccination, 36^ vs. 63% 15 weeks after inoculation, 62% vs. 
87^ at the time of slaughter, and a cummulative ratio of 77% 
vs. 100^. It was concluded that B. bronchiseptica infection in 
swine was prevented to a limited extent by vaccination. 
2 Koshimzu reported that immunization of 3-month-old 
naturally infected pigs with a B. bronchiseptica bacterin with 
adjuvant did not significantly decrease the number of B. bron­
chiseptica isolated from the nasal cavity as compared to the 
control group. Harris and Switzer (1972) reported a similar 
finding utilizing pertussis vaccine in a group of experimen­
tally infected 4-week-old pigs. 
2 Koshimizu in a trial utilizing sows immunized with a B. 
bronchiseptica bacterin approximately 40 days prior to farrow­
ing, reported that B. bronchiseptica was established in all 
pigs farrowed by the control sows while in pigs farrowed from 
^Ohmura, Y. 1972. The preventive effect of attenuated 
B. bronchiseptica on atrophic rhinitis. Unpublished data. 
Shizuoka Prefectural Animal Health Center, Japan, 
2 Koshimizu, K. 1972. Etiological studies on infectious 
atrophic rhinitis in swine. Unpublished data. Tokyo 
University. Japan. 
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the immunized sows infection was completely prevented even when 
they were challenged with B. bronchiseptica in a dose of 10^ to 
10^ organisms per 0.2 milliliter of inoculum, Kemeny (1973) 
immunized gilts with a B. bronchiseptica bacterin with adjuvant 
on the 70th and 85th day of gestation and demonstrated the 
presence of colostral agglutinating antibodies in the newly 
farrowed piglets. Eighty percent of the colostrum-deprived 
control pigs and 40 percent of the immune colostrum-fed pigs 
developed turbinate atrophy subsequent to virulent B. bronchi­
septica challenge, Harris (1970) immunized pregnant gilts with 
a B. bronchiseptica sonicate-vaccine in an attempt to passively 
immunize their offspring. The results indicated that colostral 
immunity did not induce resistance to intranasal infection or 
prevent the development of respiratory tract lesions. There 
was, however, a decrease in the number of tracheas and lungs 
positive for the organism in pigs from vaccinated sows (14 
percent) as compared to pigs from unvaccinated sows (50 per­
cent). 
The Secretory Immune System 
The newborn pig is born essentially agammaglobulinemic 
and receives immunoglobulins entirely from ingested colostrum 
(Aalund, 1972). Immune protection in the young pig is ini­
tially determined by antibody passively acquired from maternal 
colostrum by absorption from the small intestine (Porter, 1973). 
To date, 3 classes of porcine immunoglobulins have 
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been described and based on their physicochemical and antigenic 
characteristics may be considered to be analogous to the human 
immunoglobulins IgG, IgA and IgM (Porter and Allen, 1972; 
Kaltreider and Johnson, 1972). The IgG class of immunoglobu­
lins is quantitatively the most important in the pig while IgM 
is quantitatively the least abundant accounting for approxi­
mately 5 percent of the total immunoglobulin in serum and 
colostrum (Porter and Allen, 1972). Immunoglobulin M is 
believed to play an important role against gram-negative bac­
teria and provides shortlived passive immunity in neonatal 
life. 
Curtis and Bourne (1971) showed by immunochemical studies 
of post-colostral piglet serum that all 3 classes of immuno­
globulin (IgG, IgA and IgM) are absorbed. In order to ensure 
that an entire litter of newborn pigs received colostral anti­
bodies Aalund (1972) suggested that suckling be postponed until 
the entire litter was born. This would help prevent the situ­
ation where firstborn piglets deplete the amount of colostral 
immunoglobulins available for the pigs born toward the end of 
the farrowing. The immunoglobulin serum concentration of the 
neonatal pig reaches its maximum 24 hours after ingestion of 
colostrum and thereafter steadily decreases for 5 to 6 
weeks (Aalund, 1972). Porter and Allen (1972) state that 
approximately 80 percent of the immunoglobulin content in por­
cine mammary secretions is IgG. They further observed that 
although IgA is absorbed from the colostrum by the newborn pig, 
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very little secretory immunoglobulin A (SIgA) antibody is 
absorbed and it was concluded that SIgA antibody throughout lac­
tation had as its main function local defense of the alimentary 
tract. 
The discovery in the early 1960's that a secretory immune 
system develops and functions independently of the system 
responsible for the formation of circulating antibody, with 
immunoglobulin A (IgA) as the predominant immunoglobulin of 
external secretions, is the basis for the concept of the secre­
tory immunologic system (Tomasi, 1970; Waldman, 1970). 
The role of the secretory immune system in the development 
of resistance to certain viral and bacterial infections is 
becoming increasingly clear and it has become apparent that in 
mammals the burden of defense against foreign antigens is 
shared by the systemic and local immune mechanisms (Plaut, 
1972). Harris and Switzer (I969) postulated a role for the 
secretory immune system in their consideration of nasal resis­
tance in swine against reinfection by B, bronchiseptica and 
Holt (1972) stated that in order to confer true immunity to 
whooping cough it may be necessary to use aerosol immunization 
in order to stimulate a secretory immune response. Extensive 
reviews by Tomasi and Bienenstock (I968), Heremans (I968), 
Tomasi (1970), Tomasi and DeCoteau (1970), Plaut (1972), 
Bienenstock and Perey (1972), Tomasi and Grey (1972) and 
Waldman (1973) cover the historical, biochemical, immunological 
and biological aspects of the secretory immune system. 
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Key observations establishing the existance of local immun­
ity are J (1) that antiviral and antibacterial antibodies are 
present in the secretions of individuals recovered from active 
infection, (2) that the secreted antibodies are predominately 
IgA, (3) that protection against reinfection of the mucous 
membranes can best be stimulated by local application of anti­
gen to the mucous surface, (4) that if the antigen is present 
in sufficient amounts a systemic immune response may also occur, 
(5) that local immunity may be of both antibody and cell medi­
ated types, (6) that there is often no correlation between the 
levels of circulating antibody and local mucosal resistance, 
and (7) that the presence of secretory immunoglobulin A (SIgA) 
antibody correlates with protection against disease (Smith, 
1969; Waldman, 1970; Bienenstock and Perey, 1972). Bienenstock 
and Perey (1972) further state that a local immune response can 
occur after administration of parenteral antigen if sufficient 
quantity of antigen is administered or if a live replicating 
antigen (viral) is used and that not all antigens given locally 
will produce a local IgA immune response. Heremans (I968) 
stated that 4 types of cells (antigen - processing cells, 
plasma cells, intraepithelial lymphocytes and epithelial gland­
ular or mucosal cells) should be considered in understanding 
the local immune system. 
In general, all secretions which are derived from mucosal 
surfaces can be considered part of the secretory immune system 
including tears, respiratory secretions, gastrointestinal 
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secretions, colostrum and secretions of the female and male 
genital tracts (Waldman, 1973). Waldman (1973) states there 
are several components which play a role in the protection of 
mucosal surfaces against infectious agents. These include 
secretory IgA antibody, antibodies of other immunoglobulin 
classes such as IgG, IgM, IgD and IgE, cellular immunity, the 
lysozyme-complement-immunoglobulin system and interferon. 
Secretory immunoglobulin A is the predominant class of 
antibody in secretions bathing mucous membranes (Williams and 
Gibbons, 1972), but it cannot account for all aspects of local 
immunity (Smith, 1969). Waldman (1973) states IgG, IgM, and 
IgD are present in external secretions but the evidence indi­
cates that the largest quantity of these immunoglobulins reach 
the mucosal surface by simple diffusion. There is reason to 
believe, however, that in vivo the complement fixing antibodies 
may play an important role in protection against bacterial 
infection. The fact that immunoglobulin E has a powerful bio­
logical effect in releasing vasoactive substances on mucosal 
surfaces and is present in every normal individual, predicts 
some role for it in mediating normal response to antigen expo­
sure on mucosal surfaces (Smith, 1969). It has been shown 
that there are large numbers of IgE producing cells lining the 
respiratory and gastrointestinal tracts and IgE is present in 
larger amounts than would be present by simple diffusion 
(Waldman, 1973). 
Respiratory mucous secretions contain a number of 
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immunologie resistance factors which include lymphocytes and 
macrophages as well as antibody (Bienenstock and Perey, 1972). 
Waldman (1973) states that macrophages and lymphocytes contrib­
ute to cell-mediated immunity and that cell-mediated immunity 
can be induced by the local application of antigen, 
Bienenstock and Perey (1972) report that in man Mycoplasma 
pneumoniae infection, which is localized on the respiratory 
tract epithelium, does not apparently give rise to a predomi­
nately IgA antibody local response. It was shown that although 
the local antibody response was primarily IgM a major component 
of resistance in this infection was related to local lympho­
cyte -mediated immunity. It was considered by Waldman and 
Ganguly (1973) that cell-mediated immunity might play an impor­
tant role in protection and immunity on mucosal surfaces. 
Waldman (1973) reported a study of the lysozyme-complement-
immunoglobulin system that may explain how IgA antibody can 
function in a bactericidal manner. The study indicated that 
IgA antibody to Escherichea coli, plus complement and lysozyme 
led to the death of E. coli while removal of any 1 of the 
3 components did not result in the death of E. coli. 
Interferon has been detected in external secretions fol­
lowing viral infection, however, its role in the protection of 
secretory surfaces is not clearly understood (Waldman, 1973). 
Vengris and Mare (1972) showed that swine can produce inter­
feron in response to viral and synthetic inducers and stated 
that this mechanism probably plays a significant role in 
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antiviral defense in swine. 
The most widely studied immunoglobulin on secretory sur­
faces is IgA. Waldman (1973) states that serum IgA is found 
predominately in a monomeric form with a molecular weight of 
approximately 170,000 and a sedimentation coefficient of 
approximately 7, The predominant form of IgA in external 
secretions is as a dimer with a molecular weight of approxi­
mately 380,000, a sedimentation coefficient of 11 and contains 
a glycoprotein called secretory component. Secretory IgA is 
made in two different cells. The dimerized IgA is synthesized 
in the subepithelial plasma cells and secretory component is 
apparently synthesized in the epithelial cells. 
The exact biological function of secretory component is 
unknown but possible functions are transport and/or stabiliza­
tion of the molecule (Waldman, 1973). Butler (1973) states 
that secretory component is attached covalently and extracellu-
larly to an IgA dimer and that the evidence indicates that 1 
function of secretory component is stabilization of the SIgA 
molecule resulting in resistance to enzymatic proteolysis. 
Secretory IIS IgA antibodies appear to have a high degree of 
resistance to proteolytic enzymes, whereas serum antibodies are 
easily destroyed and it can be concluded that only these 
locally produced antibodies may be expected to function con­
sistently on mucosal surfaces (Freter, 1971). Porter (1973) 
considers that the secretory component also assists in the 
binding of the immunoglobulin to the mucus which coats the 
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epithelium. 
Studies have demonstrated that about 80 percent of the IgA 
found in nasal secretions is of the IIS secretory type while 
10 to 20 percent is of the 7S type and is antigenically identi­
cal to serum IgA (Tomasi and Bienenstock, 1968; Tomasi, 1972). 
The mechanisms of the "biological action of SIgA antibodies 
are being investigated at this time. Secretory IgA has been 
shown to have neutralizing activity against viruses on the 
mucosal surface and thus can prevent colonization of this site 
(Tomasi, 1972). It is not so clear, however, how SIgA anti­
bodies exert a protective effect against bacterial infections. 
Plaut (1972) reports that immunoglobulin A has no clearly 
demonstrable ability to promote phagocytosis of bacteria by 
polymorphonuclear leukocytes (opsonization). Tomasi (1972), 
however, believed it likely that IgA antibodies do promote 
phagocytosis, especially by monocytes and that this mechanism 
would apply more to particles that have penetrated below the 
mucous membrane into the submucosal area. Neither serum IgA or 
SIgA fix complement, but SIgA antibody plus complement plus 
lysozyme was reported to kill E, coli (Waldman, 1973)* Secre­
tory IgA, therefore, is not generally considered to be bacteri­
cidal, to mediate the usual complement-dependent bacterial 
lysis, or to enhance phagocytosis. 
Tomasi (1972) suggests that SIgA could act in concert with 
other nonimmunoglobulin agents produced at the mucosal surface 
and that there are indications of a new pathway by which 
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complement might be implicated in IgA-raediated antibacterial 
reactions. 
It has been shown that SIgA binds to and agglutinates bac­
teria to which it is specifically directed and may interfere 
with the attachment of the microorganism to the mucosa, thereby 
impairing its ability to penetrate the mucosa and rendering it 
more susceptible to mechanical clearing by ciliary action 
(Plaut, 1972; Gibbons, 1973). Williams and Gibbons (1972) sug­
gest that by merely binding to and agglutinating bacteria, SIgA 
may exert an immune protective function as this could influence 
bacterial adherence to and subsequent colonization of the muco­
sal surface. They demonstrated that human parotid SIgA did 
interfere with bacterial adherence to epithelial surfaces in 
vitro and thought that this function in itself would limit the 
colonization of microorganisms on mucosal surfaces and could 
be the major mechanism of immunity mediated by secretory 
immunoglobulins, 
Pubara and Freter (1973) reported that purified antibody 
preparations, obtained from the lumen of the intestine of 
orally vaccinated germfree mice, contained very small amounts of 
SIgA but that no other serologically active immunoglobulins 
were found that could protect mice against experimental cholera 
infection. This is the first time that protection against a 
bacterial infection has been demonstrated with purified prepar­
ations of SIgA antibodies. 
Reynolds and Thompson (1973a and b) report that in rabbits 
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immunized with Pseudomonas aeruginosa, the immunoglobulin 
class stimulated that had antibody activity in bronchial secre­
tions was a function of the immunizing route. Parenteral 
injections resulted in only IgG antibody in the bronchial 
secretions, probably as a result of simple diffusion. Intrana­
sal immunization, in contrast, produced agglutinins in the 
mucosal secretions of both IgA and IgG class. Immune IgA was 
shown to inhibit the growth of pseudomonas serotypes, but this 
effect was not mediated by complement and was thought to be 
related to the agglutinative effect of IgA, 
Gibbons (1973 and 1974) observed that bacterial adherence 
to a mucosal surface was a parameter which should relate to the 
virulence of pathogenic organisms. Several correlations 
between the ability of pathogenic bacteria to adhere to mucosal 
surfaces and their virulence are reviewed by Gibbons (1973 and 
1974). These are as follows: (1) pathogenic strains of Myco­
plasma species have been found to adhere to tracheal epithelial 
cells, while nonpathogenic strains generally do not, (2) viru­
lent strains of Streptococcus pyogenes possessing M protein 
firmly adhere to human oral and pharyngeal epithelial cells, 
whereas an avirulent strain lacking M protein adhered poorly, 
and (3) pathogenic strains of Escherichea coli possessing k88 
antigen have been observed to adhere better to segments of 
small intestine than avirulent strains lacking this antigen. 
Ellen and Gibbons (1972) presented data indicating that the 
surface "fuzz" of S. pyogenes which is known to contain M 
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protein, functions in the attachment of the organism to epithe­
lial surfaces. 
Gibbons (1973) observed that when colonization by a path­
ogen progresses slowly and elicits a secretory antibody 
response comparable to that imposed against indigenous bacteria, 
the pathogen could exist in a transient balanced or "carrier 
state" in which its adherence and colonization would be similar 
to that of indigenous bacteria. Artenstein (I969) stated that 
while there is a lack of information on antibacterial activity 
in nasal secretions that for several species of bacteria there 
is well documented evidence of local immunity. 
Live agents, either in the form of natural pathogens or 
live attenuated vaccines, elicit better immunity than do killed 
organisms (Waldman and Ganguly, 1973; Bellanti, 1969), 
Bellanti (1969) reported that both nasal secretion and serum 
antibody response followed induced experimental F. tularensis 
infection or parenteral immunization with a live, attenuated 
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tularemia vaccine containing approximately 10 viable cells. 
Waldman and Ganguly (1973) state however, the same results 
could theoretically be obtained by administering the inacti­
vated organisms repeatedly and in larger doses. It is known 
that secretory antibody response can be elicited by parenter-
ally administered vaccines probably by transportation of the 
antigen to the secretory lymphoid tissue, but such levels of 
local antibody are usually low and result in only partial pro­
tection (Waldman and Ganguly, 1973). They further noted that 
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optimal mucosal antibody response against microorganisms may 
be induced by either natural infection or by direct application 
of killed or live attenuated organisms to the mucosal surface. 
Ogra and Karzon (I969) presented evidence to indicate that 
the output of SIgA antibody from mucosal surfaces is anatomic­
ally restricted to the site where antigen stimulation has 
occurred. Live, attenuated poliovirus was used to immunize 
children with double-barrelled colostomies. Secretory IgA 
responses were confined to the part of the colon vaccinated and 
no other local response occurred, although there was a marked 
serological response. When killed poliovirus vaccine was 
administered the response was confined to the site vaccinated 
and there was no serological response. 
Waldman et (1970) observed influenza antibody 
response following aerosol administration of inactivated virus. 
They noted that large particle aerosols (40 to 100 u) or nose 
drops were the most effective in the stimulation of nasal anti­
body while the highest serum antibody responses resulted from 
aerosolization of small particle (1.5 u) size. In several 
field trials with influenza vaccine, the aerosol route of immu­
nization gave protection rates of 70 to 80 percent, 
Tomasi and DeCoteau (1970) noted that F. tularensis admin­
istered intranasally immunized subjects so that they were 
resistant to subsequent aerosol challenge with live organisms, 
but that this resistance could be overcome even in the presence 
of significant titers of nasal antibody if higher doses of the 
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organism were administered. Waldman and Ganguly (1973) stated 
that both local and systemic immune mechanisms are related to 
protection against disease, but that mucosal colonization is 
more effectively inhibited by local immunity. 
In humans, small-particle aerosol immunization utilizing 
inactivated influenza virus vaccine appears to be the most 
effective method of immunoprophylaxis (Waldman et aJL,  1973). 
Aerosol administration of parainfluenza type 2 vaccine to 
humans was shown to be a more effective stimulus of antibody 
in respiratory secretions than subcutaneous administration 
(Wigley et , 1970). Live attenuated rubella virus (Ganguly 
et al., 1973) was shown to stimulate respiratory secretion 
antibody when given by aerosol. Protection after nasal chal­
lenge appeared to be best in those groups which had the highest 
nasal secretion antibody response after immunization. Wigley 
et al. (1969) demonstrated that soluble tetanus toxoid given as 
an aerosol led to an increase in serum antibody titers compar­
able to those resulting from subcutaneous injection and that 
sputum antibody titers significantly increased. The sputum 
antibody titers were due to the production of secretory anti­
body. Buscho et al. (1972) reported that intranasal vaccina­
tion of human volunteers with an inactivated rhinovirus type 13 
(RVI3) vaccine induced resistance to challenge that lasted 6 
months. The local neutralizing antibody which developed was 
specific for RV13 and this antibody persisted for at least 330 
days post vaccination. The suggestion was made that the local 
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respiratory tract immune response possesses some degree of 
immunologic memory. It was concluded that intranasal immuni­
zation (nosedrops) with an inactivated RV13 vaccine was more 
effective in inducing nasal immunity than parenteral adminis­
tration of this vaccine. It has been shown in man that res­
piratory tract resistance to infection by rhinovirus, parain­
fluenza viruses, and influenza virus is more closely correlated 
with antibodies present in nasal secretions than with circula­
ting antibodies and that these nasal secretion antibodies are 
more consistently produced following intranasal administration 
than by parenteral injection (Todd, 1973). 
Barclay et aj. (1973) reported that Bacillus Calmette-
Guerin bacterin administered by aerosol to rhesus monkeys 
induced a much greater degree of protection against aerosol 
challenge with virulent Mycobacterium tuberculosis than the 
same bacterin administered by intracutaneous vaccination, Nash 
and Holle (1973 ) working with guinea pigs immunized with DNP-HGG 
administered either by direct injection into the lower respira­
tory tract or intravenously, made the following observa­
tions: that systemic immunity could be as effective as local 
immunity in terms of the appearance of sensitized cell popula­
tions in the respiratory tract; that circulating, sensitized 
lymphocytes could be induced to enter the respiratory tract 
following local administration of a nonrelated substance» and 
that under specified conditions, systemic immunity (cell medi­
ated immunity) combined with local antigen administration, may 
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be the most efficient procedure for obtaining an effective 
local immunity. 
Rouse (1971) states that in the horse as in man, nasal 
antibody seems to be intimately associated with protection 
against influenza. High levels of nasal antibody were produced 
by the use of parenteral injections containing sufficient anti­
gen and Preund's adjuvant. It was presumed that if the anti­
genic stimulation is sufficient, then either the antigen circu­
lates and stimulates the antibody producing cells in the res­
piratory tract, or the respiratory tract is colonized by anti­
body producing cells migrating from the vaccination site, 
Collins and Carter (1972) reported that mice receiving 
living, attenuated Salmonella enteritidis intragastrically 
developed an effective antisalmonella immunity against subse­
quent reinfection, 
Duncan and Thomson (1970a) hypothesized that under normal 
circumstances a host can maintain an attenuated infection of 
the upper respiratory tract, but that with a decrease or alter­
ation of the specific immunity the organism can proliferate and 
lead to the development of the disease state. They demon­
strated that Pasteurella hemolytica was capable of colonizing 
the nasal passages of cattle in the presence of specific nasal 
and serum indirect hemagglutinating antibody. Bull and McKee 
(1928) reported that in the rabbit specific upper respiratory 
tract antibody to pneumococcus was responsible for the nasal 
rejection of the same strain, but specific antibody to Bacillus 
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bronchiseptica did not influence its nasal residence, Duncan 
and Thomson (1970b) reported that aerosol vaccination of calves 
with live Pasteurella hemolytica resulted in a significant 
nasal antibody response while parenterally vaccinated calves 
with equivalent serum titers had no significant nasal antibody 
response. Acquired immunity was said to be more effective in 
controlling the manifestation of disease than in preventing the 
establishment of infection. 
Todd et ad. (1971) showed that an avirulent strain of 
infectious bovine rhinotracheitis (IBR) virus used as an intra­
nasal vaccine was capable of eliciting a higher humoral anti­
body response than presently available intramuscular vaccines 
and that such an intranasal vaccine also stimulated the produc­
tion of secretory antibodies. Gutekunst et (1969) reported 
that calves intranasally vaccinated with parainfluenza-3 (PI-3) 
virus vaccine were better protected against infection than were 
intramuscularly vaccinated animals. Preliminary studies 
indicated that an animal could be immunized against PI-3 infec­
tion by intranasal inoculation of vaccine in the presence of 
significant levels of maternal serum-neutralizing antibodies, 
since there is no significant spill-over of circulating anti­
bodies into the respiratory system, Todd (1973) states that 
subcutaneous administration of formalin-inactivated PI-3 virus 
failed to elicit nasal secretory antibodies after a single 
injection, but did evoke secretory antibodies following a 
booster dose 2 to 3 weeks later. Nasal secretion 
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antibody was said to persist for a relatively short time (6 to 
8 weeks) following the initial response, but can be expected to 
persist at higher levels for prolonged periods following 
restimulâtion, 
Porter (1973) states immunohistological studies in the pig 
have defined a local secretory immune system mediated by an 
immunoglobulin analogous to human IgA, This immunoglobulin is 
synthesized in plasma cells situated in the tissues close to 
the epithelium of those organs which are in intimate contact 
with the external environment and thus is the predominant immu­
noglobulin in the secretions of the gastro-intestinal, respira­
tory, and genito-urinary tracts and of the mammary, lacrimal 
and salivary glands. 
Porcine IgA has been isolated and characterized from 
serum and mammary secretions (Bourne, 1969a and b; Vaerman and 
Heremans, 1970) and IgA concentrations in porcine sera and 
mammary secretions have also been determined (Curtis and 
Bourne, 1971). Vaerman and Heremans (1970) reported that pig 
serum and milk IgA closely resembled its human counterpart, 
however, the major part of pig serum IgA seemed to consist of 
lOS dimer molecules as compared to the predominant human 7S 
monomer. Curtis and Bourne (1971) found IgG to be the main 
immunoglobulin of sow serum and colostrum while IgA was the 
major immunoglobulin of milk. The role of IgA in milk was 
thought to be two-fold: to protect the mammary gland and to 
provide adequate levels of antibody to the intestinal mucosa 
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of young pigs until the intestinal secretory immunoglobulin 
system is fully developed. 
Bourne and Curtis (1973) reported that milk IgA is almost 
entirely (90 percent) locally produced, but that considerable 
amounts of IgG and IgM (40 percent) are also formed in the 
mammary tissue. All colostral IgG and a high proportion of IgM 
was reported to be of serum derivation as was 40 percent of the 
IgA, It was suggested that colostrum was not a true secretion 
since 90 percent of its immunoglobulin content is of serum 
origin, Svendsen and Brown (1973) measured IgA levels in the 
sera of pigs from birth to maturity and in the colostrum of 
their dams. Immunoglobulin A synthesis in young colostrum-fed 
pigs reached a significant level by 6 weeks of age and adult 
levels were reached by 18-21 weeks of age. Significant differ­
ences in IgA concentrations in secretions from individual 
glands of the same sow and from different sows were demon­
strated and it was postulated these differences may be part of 
the explanation for some of the variations between pigs in 
their susceptibility to enteric infections. 
Studies of the ontogenesis of the intestinal secretory 
immune response have not yet been reported in the literature 
(Allen and Porter, 1973%), however, they observed that the 
local immune response may commence predominately with IgM 
synthesis. In both the human infant and the pig IgM appears 
in the serum during the first week of life while IgA is not 
detected until several days later, Allen and Porter 
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(1973 a and b) demonstrated that the onset of active secretion 
of intestinal IgA did not occur before the second week of life. 
They stated that the major antigenic stimulus for the develop­
ment of IgA synthesizing cells in the lamina propria appeared 
to be the enteric flora. 
Saif et a^, (1972) reported that in the milk and colostrum 
from sows naturally or experimentally infected with live trans-
missable gastroenteritis (TGE) virus, IgA is the predominant 
immunoglobulin class of TGE antibodies. In the serum of such 
animals TGE antibody appeared to be associated with both IgA 
and IgG classes, but with more of the antibody activity in the 
IgG fraction. In contrast, intramuscular vaccination of sows 
with live attenuated TGE virus produced predominately if not 
entirely IgG antibodies in the serum, colostrum and milk. The 
mechanism accounting for the predominance of IgA TGE antibodies 
in the milk and colostrum of naturally and experimentally 
infected swine is not known, however, it was suggested that 
plasma cells either of local origin or relocated from the 
intestinal tract may be the source of mammary gland IgA TGE 
antibodies, Bohl et aj, (1972) stated the limited effective­
ness of live, attenuated TGE vaccines, especially when adminis­
tered by the intramuscular route is probably due to the produc­
tion of IgG rather than IgA antibodies in mammary secretions. 
Immunoglobulin A TGE antibodies were shown to provide more ade­
quate passive immunity than IgG TGE antibodies. 
Harris (1970) demonstrated antibodies against 
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B. bronchiseptica in concentrated nasal washings collected 
from pigs cleared of B. bronchiseptica nasal infections and 
from pigs receiving a sonicated B. bronchiseptica vaccine both 
before and after nasal challenge with a virulent B. bronchisep­
tica strain. 
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MATERIALS AND METHODS 
Source of Bordetella bronchiseptica Isolates 
Three isolates of B. bronchiseptica were used: (1) Viru­
lent strain B was isolated^ from a pig with turbinate atrophy 
and had been previously used to produce turbinate atrophy in 
experimental swine (Ross £t al., 1963b; Harris and Switzer, 
1968). (2) Strain 55 was isolated^ in 1955 from the pneumonic 
lungs and normal nasal cavity of an experimental pig inoculated 
intranasally with crude pneumonic swine lung suspension. The 
initial inoculum was secured from a pig in a herd experiencing 
clinical atrophic rhinitis and pneumonia. This organism was 
seeded into rubber stoppered 100 milliliter vials of tryptose 
phosphate broth (TPB) in 1955 and incubated at 37°C. These 
vials were then committed to a duration of survival trial. The 
cultures were sampled several times during the ensuing years 
and found to be viable. In January of 1972, after I7 years 
without serial passage, contents of a vial were cultured on 
5 percent horse blood agar. Two extremely rough bacterial 
colonies developed and 1 colony was picked into TPB. This 
organism was subsequently identified as a highly modified B. 
bronchiseptica and designated as strain 55. (3) An isolate of 
B, bronchiseptica designated low-virulence D-1 strain was 
^Dr. W. P. Switzer, Veterinary Medical Research Institute, 
Iowa State University, recovered this isolate. 
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isolated^ from a puppy infected with canine distemper. Strain 
D-1 had been shown in a previous study to be incapable of caus­
ing turbinate atrophy in swine (Ross ejt a2,, I967), 
Culture Media 
Bordetella bronchiseptica was isolated from swab speci­
mens by inoculation onto MacConkey's agar with crystal vio-
let modified by the addition of 1 percent dextrose (Ross, 
1963). The MacConkey's agar was further modified to retard 
overgrowth of the cultures by bacterial and fungal contamination. 
The modifications were as follows 1 (1) Furaltadone^ (NF-260) 
was added to the medium at a concentration of 0,02 mg./ml. 
The Furaltadone (0,01 gram) was autoclaved separately in 
250 ml, of distilled water and added to 250 ml, of double 
strength MacConkey's agar with crystal violet and 2 percent 
dextrose. Bordetella bronchiseptica isolates were found to be 
resistant to Furaltadone at the 0.02 mg./ml. level while many 
common contaminating organisms contributing to overgrown plates 
were significantly inhibited. (2) After autoclave steriliza­
tion and cooling to 45°C, 50 units of Mycostatin^ was added to 
each milliliter of the medium. Fungal contamination of nasal 
^Dr. R. F. Ross, Veterinary Medical Research Institute, 
Iowa State University, recovered this isolate. 
2 Difco Laboratories, Incorporated, Detroit, Michigan. 
3 
Norwich Pharmacal Company, Norwich, NewYork. 
ii 
E. R. Squibb & Sons, Incorporated, New York, New York. 
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swab cultures was completely prevented by this procedure with­
out interfering with the isolation of B. bronchiseptica. 
Horse blood agar composed of 5 percent defibrinated 
horse blood in tryptose blood agar base medium^ was used to 
determine bacterial titers expressed as colony forming units, 
purity checks at all stages of vaccine production and serial 
passage through embryonating 6 to 8 day old hen eggs and for 
hemagglutination (HA) studies. 
Muelier-Hinton agar medium^ was used for sulfamethazine 
sensitivity testing and tryptose blood agar base in Roux 
flasks was used for vaccine production. Fluid cultures of 
Bordetella bronchiseptica were propagated in tryptose phosphate 
broth^ (TPB). Media for the biochemical identification of B. 
bronchiseptica were obtained from a commercial source.^ 
Identification of Bordetella bronchiseptica 
Forty-eight hour cultures of B, bronchiseptica on modi­
fied MacConkey's agar incubated at 37°C appeared as grayish-
tan colonies with a decolorized alkaline zone surrounding the 
colony. Further identification was based on an alkaline reac­
tion in dextrose broth and lactose broth, hydrolysis of urea 
within 4 hours, utilization of citrate, alkalinization of 
litmus milk in 48 to 72 hours and a positive hemagglutination 
reaction. 
^Difco Laboratories, Incorporated, Detroit, Michigan. 
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Preparation of Buffered Solutions 
Phosphate buffered saline (PBS)» 
The PBS was composed of the followingi 
NagHPO^ (0.1 M) 85.7 ml. 
KHgPO^ (0.1 M) 14.3 ml. 
Saline (0.85 percent NaCl) 900.0 ml. 
The above solution was pH 7,4. 
Veronal buffered diluent (VBD)i 
Stock solution was composed of the followingi 
NaCl 83.00 gm. 
Na-5, 5-diethyl barbiturate 10.19 gm. 
Distilled H^O 1867.23 ml. 
HCl (1 N) 34.58 ml. 
Solution containing 
MgClg (1 M) and CaClg (0.3 M) 5.00 ml. 
The VBD was composed of the followingi 
Stock solution 100.00 ml. 
Distilled H^O 400.00 ml. 
Gelatin (0.25 percent) 16.00 ml. 
The VBD was pH 7.4 and was stored at 4-8°C. It was used 
within 24 hours of preparation, 
Bordetella bronchiseptica Inocula 
Cultures of B. bronchiseptica used in transmission exper­
iments were stored lyophilized in low passage. Strain B inocula 
for intranasal challenge was prepared by injecting 0.1 ml. of 
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24 hour TPB cultures into the yolk sac of 6 to 8 day old embry-
onating hens eggs. The embryos were incubated at 37°C and 
candled daily. Embryos dying after 24 hours incubation were 
incubated an additional 24 hours. Yolk sac fluids were har­
vested aseptically, pooled, checked for purity on 5 percent 
horse blood agar and stored frozen at -20°C. The pooled egg 
yolk fluid inocula containing B strain B. bronchiseptica had 
approximately 9 x 10^ colony forming units per milliliter. 
Strain 55 B, bronchiseptica was checked for ability to 
regain swine virulence by serial passage in embryonating hens 
eggs. One-tenth ml. of fourth passage 24 hour TPB culture was 
injected into the yolk sac of 6 to 8 day old embryonating hens 
eggs. The embryos were incubated at 37°C and candled daily. 
The yolk sac fluids were aseptically harvested from the dead 
embryos, pooled, purity checked on 5 percent horse blood 
agar and used to inoculate the next group of 6 to 8 day old 
embryonating hens eggs for 11 serial passages. The eleventh 
passage was stored at -20°C until used. The pooled egg yolk 
n 
fluid had approximately 1 x 10' colony forming units per 
milliliter. 
Intranasal Inoculation of Pigs 
Pigs were inoculated intranasally by inserting the tip of 
a syringe into the external naris and discharging 0.5 ml. of the 
challenge inoculum into each nostril. The injection of the egg 
yolk inoculum into the nasal cavity was timed with the 
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inspiration of the pig being challenged. 
Preparation of Vaccines 
Strain D-1 sonicate, whole-cell, formalinized bacterin 
Two to 5 milliliters of a 24 hour tryptose phosphate 
broth (TPS) culture of seventh, eighth or ninth passage D-1 
strain B, bronchiseptica was inoculated onto tryptose blood 
agar base (without blood) in Roux flasks and incubated at 37°C 
for 24 hours without inversion of the flasks. The growth was 
harvested at 24 hours by washing with 20 milliliters of physio­
logical saline solution (PSS) per Roux flask. Glass beads were 
used to loosen the growth from the agar. The harvested growth 
was sonicated in 50 to 100 milliliter volumes in a Raytheon 
model DFlOl sonic oscillator^ for 2.5 minutes. The titer of the 
bacterial suspension was determined by culturing 10-fold dilu­
tions onto 5 percent horse blood agar both prior and subse­
quent to the sonication procedure. A 1 log drop in the bac­
terial titer usually occurred post sonication. The sonicated 
culture was inactivated with a final concentration of 1:1000 
formalin at 4°C for 48 hours. The 4°C temperature was selected 
because the hemagglutination (HA) titers of the bacterins were 
maximized by inactivation at refrigerator temperatures. Strain 
D-1 sonicate bacterin was generally prepared prior to each 
experiment and the approximate number of organisms per 
^Raytheon Company, Norwalk, Connecticut. 
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milliliter of bacterin after sonication varied from 8 x 10 to 
2 X 10?. 
Adjuvanted parenteral bacterins were prepared as followsi 
The parenteral bacterins were emulsified with equal parts of 
adjuvant by repeated passage through an l8-gauge needle attached 
to a 20 milliliter syringe. 
Strain D-l, whole-cell, formalinized bacterin 
Two milliliters of a 24 hour TPB culture of seventh pas­
sage D-l strain B. bronchiseptica was inoculated into Roux 
flasks containing tryptose blood agar base (without blood) and 
incubated for 48 hours at 37°C without inversion of the flask. 
The growth was harvested at 48 hours with 20 ml. of PSS with the 
aid of glass beads. The titer expressed as colony forming units 
was determined on 5 percent horse blood agar. The culture 
was formalinized with a final concentration of 1:1000 formalin, 
inactivated for 24 hours at room temperature and then refriger­
ated at 4°C, The bacterial concentration was approximately 
1 X 10^® organisms per milliliter. 
Strain 9$, whole-cell, formalinized bacterin 
A whole-cell bacterin using fourth passage 55 strain B. 
bronchiseptica was prepared utilizing the same procedure as used 
for the D-l whole-cell bacterin. The bacterial concentration 
was approximately 2 x 10^® organisms per milliliter. 
6l 
Partially purified Bordetella bronchiseptica hemagglutinin 
extract 
Bordetella bronchiseptica hemagglutinin was extracted by 
a modification of the technique employed by Masry (1952). The 
extraction procedure was as followsi (1) Five milliliters of 
seventh passage D-1 strain B. bronchiseptica 24 hour TPB culture 
containing approximately 2 x 10^ organisms/ml. was inoculated 
onto tryptose blood agar base (without blood) in 6 Roux flasks 
and incubated at 37°C for 24 hours with the agar down, (2) The 
growth was harvested after 24 hours incubation with 15 ml. of 
1 M sodium acetate per flask. Glass beads were used to loosen 
the growth from the agar. The harvest was pooled and incubated 
at 37°C for 48 hours. (3) The sodium acetate-bacterial suspen­
sion was centrifuged at 4°C for 1 hour at 10,000 Xg, The 
supernatant was retained. The pH was adjusted to 6.7 to 6.9 
with 1 N sodium hydroxide, and cooled to -3°C. (4) Methanol 
cooled to -20°C was used in the extraction process. The super­
natant was placed in a 250 ml. Erlenmeyer flask in a salt 
water ice bath kept at approximately -5°C. Methanol at -20°C 
was added to the supernatant with constant stirring at a rate 
of 2 ml./minute until methanol was 40 percent of the total 
volume. (5) The resultant solution was kept at -20°C for 24 
hours and then centrifuged at 10,000 Xg for 1 hour at -10°C 
in a Beckman L2-65B ultracentrifuge.^ The centrifugate was 
^Beckman Instruments, Inc., Spinco Division, Palo Alto, 
California. 
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harvested with 5 milliliters of PBS, checked for hemagglu­
tinin content, and stored at -20°C. 
Live, low-virulence 55 strain Bordetella bronchiseptica intra­
nasal vaccine 
Three milliliters of sixth passage 55 strain B. bronchi­
septica 24 hour TPB culture was inoculated into cotton-
stoppered flasks containing 50 ml. of TPB and incubated at 37°C 
for 24 or 48 hours. The live seventh passage TPB cultures of 
55 strain were used for intranasal vaccination. Twenty-four 
hour cultures were administered for the first dose and 48 hour 
cultures were used for the second and subsequent doses. The 24 
hour 55 strain seventh passage TPB culture contained approxi­
mately 1 X 10^ organisms/ml. and the 48 hour TPB culture approx­
imately 1 X 10^ organisms/ml. The vaccines were administered 
on the day of their preparation. 
A dosage of 0.5 ml. per nostril of the 24 and 48 hour 
TPB cultures in the form of nosedrops was administered to each 
intranasally immunized pig. The tip of a 5 milliliter 
syringe was inserted into each nostril and used to instill the 
TPB culture into the nasal cavity. Administration of the cul­
ture was timed with the inspiration of the pig. 
Strain 55 Bordetella bronchiseptica TPB culture sterile filtrate 
intranasal vaccine 
Three milliliters of sixth passage 55 strain B. bronchi­
septica 24 hour TPB culture was inoculated into 50 ml, of TPB 
and incubated at 37°C for 24 hours. The 55 strain TPB culture 
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was passed through a 0,^5 micrometer Millipore filter,^ The 
filtrate was sterility checked on 5 percent horse blood agar 
and stored at 4°C. The TPB culture contained approximately 
1 X 10^ organisms/ml. prior to filtration. The 55 strain ster­
ile filtrate was administered in the same manner as the live 55 
strain intranasal vaccine. 
Source and Care of Experimental Swine 
Experimental swine were obtained from 4 sourcesi 
(1) From a Bordetella bronchiseptica rhinitis infected Iowa 
State University production herd, Ames, Iowa, (2) from a Borde-
tella bronchiseptica rhinitis free commercial herd, Ames, Iowa, 
(3) from a Bordetella bronchiseptica rhinitis free purebred SPF 
herd, Clear Lake, Iowa, and (4) from the respiratory-disease-
free herd maintained by the Veterinary Medical Research Insti­
tute, Ames, Iowa. 
The Veterinary Medical Research Institute respiratory-
disease -free herd was originated in 1951 from surgically 
derived stock and maintained as an isolated herd since that 
time. The ration fed to the herd and all experimental swine 
did not contain antibiotics, sulfonamides or arsenicals. The 
feed contained a calciumiphosphorus ration of 1.9:1 based on 
calculation of phytophosphorus as 30# available. Newborn pigs 
were injected intramuscularly with 2 milliliters of 
^Millipore Filter Corporation, Bedford, Massachusetts. 
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Dexiron 100^ at 7 days of age. The pigs had access to a 
preweaning meal starter ration (19 percent protein) beginning 
at 1 week of age and were weaned at approximately 5 weeks 
of age, A grower ration (17 percent protein) was fed in the 
herd from the fifth week of age. Experimental pigs weaned from 
the supply herd were fed the grower ration while on experiment. 
Pregnant dams brought to the Veterinary Medical Research 
Institute for experimental purposes were housed in individual 
farrowing units and fed a gestation-lactation ration (12 per­
cent protein). Newborn pigs were injected intramuscularly with 
2 milliliters of Dexiron 100 at 3 to 5 days of age. The pigs 
were fed the preweaning meal starter ration until weaning age 
(5 weeks) and then were placed on grower ration for the dura­
tion of the experiments. 
Animal Experiments 
Experimental pigs were housed in individual isolation 
units or at the Veterinary Medical Research Institute hilltop 
swine rearing unit. 
Collection of Specimens 
Nasal secretions were collected jja vivo on sterile cotton-
2 tipped plastic stemmed applicator sticks by inserting a separ­
ate sterile swab into each nostril and gently twisting. The 
^Norden Laboratories, Lincoln, Nebraska, 
p 
Tomac, American Hospital Supply, Evanston, Illinois, 
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external nares were cleaned prior to nasal sampling with a cot­
ton pledget saturated with 70 percent ethyl alcohol and then 
squeezed dry. The swabs were inserted into the nares at a slight 
angle with the cotton tip directed toward the nasal septum and 
twisted with gentle pressure until the area of the second cheek 
tooth was reached. In very young pigs the cotton tip of the 
nasal swab was all that was inserted into the nasal cavity. 
Samples of nasal secretions from the ethmoid turbinates for 
"bacterial culture were collected at necropsy by sectioning the 
head longitudinally and carefully removing the medial septum, 
A sterile swab was then used to obtain secretions from the pos­
terior portion of the nasal cavity. The secretions gathered on 
the paired nasal swabs were streaked as soon as possible on the 
selective modified MacConkey's medium. The nasal swabs were 
thoroughly rubbed over the surface of the culture medium with a 
twisting motion in 3 different directions. 
Necropsy Procedures 
Experiments were terminated by either animals being killed 
by electrocution and exsanguination at the Veterinary Medical 
Research Institute with immediate necropsy or by the animals 
being sent to commercial swine slaughter plants where gross 
examinations were made after processing. 
The procedure for the determination of gross turbinate 
atrophy was as followsi A cross-section of the nasal cavity 
was made at the level of the first premolar tooth. Gross 
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distortion or atrophy of the nasal turbinates and nasal septal 
defects were characterized depending on severity as mild, mod­
erate or severe. 
Determination of Resistance to Sulfamethazine 
in Bordetella bronchiseptica 
Sulfamethazine sensitivity of B, bronchiseptica isolates 
was determined by utilizing Mueller-Hinton agar medium and sul­
famethazine sensitivity discs containing approximately 0.15, 
0,30, 0.60 or 0,90 milligrams of sulfamethazine^ per 1/4 inch 
disc. The sulfamethazine discs were prepared by saturating 
2 blank discs in solutions containing 5. 10, 20 and 30 milligrams 
of sulfamethazine per milliliter. Each disc was expected to 
retain about 0.03 ml. of the solution prior to drying. The sul­
famethazine saturated discs were dried overnight in a 37°C 
incubator. A culture was considered sensitive if B„ bronchisep-
tica was inhibited by the disc saturated in the 5 or 10 mg./ml. 
solution. Sensitivity to the discs saturated in the 20 and 30 
mg./ml. solutions was recorded as S20 or 330, Isolates not 
inhibited by the discs saturated in the 30 mg,/ml, solution 
were considered resistant. 
Sulfamethazine, Vet Products Corporation, Kansas City, 
Missouri. 
2 Schleicher & Schuell, Inc,, Keene, New Hampshire. 
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Preparation of B. bronchiseptica 
for Electron Microscopy 
Bordetella bronchiseptica 55 and B strain thin sections 
were prepared in the following manneri Forty-eight hour TPB 
cultures were pelleted by centrifugation and fixed for 45 min­
utes in 1.5 percent cold glutaraldehyde in Milloning's phos­
phate buffer at pH 7.2. They were post-fixed in buffered 1 per­
cent osmium tetroxide for 1 hour. The pellets were embedded 
in Epon 812 epoxy resin^ and the capsules were incubated accord­
ing to the following schedule: overnight at 35°C, 24 hours at 
45°C and 24 hours at 6o°C. After polymerization, sections were 
cut and stained in uranyl acetate and lead citrate. The grids 
were examined with a Hitachi HS-8 electron microscope. 
For negative contrast staining, the following procedure 
was utilized:^ Strain 55 and B strain B. bronchiseptica was 
grown for 24 and 48 hours on 5 percent horse blood agar or 
in TPB. The preparations were negatively stained with neutral­
ized phosphotungstic acid. A drop of lightly centrifuged TPB 
culture centrifugate or a cotton-tipped swab with organisms 
from the agar cultures was added to a spot plate well containing 
3 to 4 drops of 4 percent phosphotungstic acid, 15 to 20 
^Polysciences Inc., Rydal, Pennsylvania, 
2 C. L. Annis, Veterinary Medical Research Institute, 
Ames, Iowa. 
^A. E. Ritchie, National Animal Disease Laboratory, 
Ames, Iowa, 
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drops of water and 1 to 2 drops of a freshly prepared approxi­
mately 0.1 percent bovine serum albumin solution. After mixing, 
the preparations were sprayed on carbon-coated colloidion-filmed 
grids with a Vaponefrin all-glass nebulizer.^ The grids were 
2 immediately examined in a Phillips EM-200 electron microscope. 
Particulate Antigen Settling Test 
The particulate antigen settling test (PAST) was utilized 
as described by Harris (1970) and Harris and Switzer (1972). 
Preparation of PAST antigen 
Strain D-1 bronchiseptica was grown in TPB for l6 hours 
at 37°C. A 1 milliliter aliquot was then inoculated into 
550 ml. of TPB in a 1000 ml, Erlenmeyer flask and incubated for 
20 to 24 hours at 37°C. Formalin was added to the flask at a 
1:1000 concentration and incubated at 37°C for another 20 to 24 
hours. Blood agar cultures were made to verify that the orga­
nisms were inactivated by this treatment. The cells were har­
vested by centrifugation at 4-8°C at 15,000 Xg for 1 hour, 
resuspended in 0.85 percent NaCl solution containing 1:1000 
formalin and stored at 4°C. 
3 The test was conducted in plastic microtitration trays 
^ Vaponefrin Company, New York, New York. 
2 A. E, Ritchie, National Animal Disease Laboratory, 
Ames, Iowa. 
^Linbro Chemical Company, New Haven, Connecticut. 
69 
with U-shaped wells. Diluent was 5 percent NaCl solution. 
Diluent was added to all wells in 0,05 ml, amounts with a drop­
per^ and 0,05 ml, of serum was added to the first well. Serial 
2 two-fold dilutions were made with a diluter which carried 0,05 
ml, of fluid from 1 well to the next. 
The appropriate antigen dilution (0,05 ml.) was added to 
each well. The plate was covered with a plastic sealer, shaken 
for 2 minutes on a mechanical shaker^ and incubated at 37°C 
for 2 hours. The trays were kept at 4°C for 48 to 72 hours. 
After incubation the results were read with the aid of a mirror. 
The B, bronchiseptica antigen suspension was diluted in 
0.85 percent NaCl solution containing 1:1000 formalin to a con­
centration that registered 120 to 130 nephlos units as deter-
4 
mined by a Coleman Nepho-colorimeter set to a standard of 79. 
This was determined to be the optimum working antigen 
concentration, 
Bordetella bronchiseptica Hemagglutination 
A characteristic of B. bronchiseptica is its ability to 
agglutinate red blood cells. This characteristic is not known 
to be shared with other closely related organisms except 
^Linbro Chemical Company, New Haven, Connecticut, 
2 Cooke Engineering Company, Alexandria, Virginia, 
^A. H. Thomas Company, Philadelphia, Pennsylvania. 
h 
Coleman Instruments Corporation, Maywood, Illinois. 
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members of the genus Bordetella and can be used as an additional 
diagnostic tool in the identification of B. bronchiseptica. 
A B. bronchiseptica colony was suspended in a drop of PSS 
on a glass slide or a brucellosis test box. The colonies were 
picked from 24 hour cultures as aged cultures tend to lose their 
ability to agglutinate red blood cells. A drop of approximately 
3 percent washed sheep red blood cells (SRBC) was added to 
the bacterial suspension and mixed. A drop of SRBC was added 
to a drop of PSS as a control. The slide was rotated to insure 
adequate mixing. Hemagglutination occurred within 1 to 8 
minutes. 
Determination of B. bronchiseptica hemagglutination (HA) titers 
Three milliliters of sixth passage 55 strain, ninth pas­
sage D-1 strain, and eighth passage B strain B. bronchiseptica 
24 hour TPB cultures were inoculated onto 5 percent horse 
blood agar and tryptose blood agar base in Roux flasks and into 
25 milliliters of TPB. Blood agar cultures were incubated 24, 
48 and 72 hours, tryptose blood agar base cultures were incu­
bated 24 and 48 hours and TPB cultures were incubated 24 hours 
at 37°C. The 24, 48 and 72 hour blood agar cultures and 24 and 
48 hour tryptose blood agar base cultures were harvested with 
20 milliliters of PSS. The bacterial suspensions in PSS and 
the TPB cultures were pelleted by centrifugation. The superna­
tant was discarded and the bacteria were resuspended to a 2 
percent concentration in PSS. 
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The hemagglutination test was done in plastic trays with 
V-shaped wells. Diluent for the 2 percent bacterial suspensions 
was Veronal buffered diluent (VBD) with gelatin. Diluent was 
added to all wells in 0,05 ml. amounts with a dropper and 0.05 
ml. of the 2 percent bacterial suspensions was added to the 
first well. Dilutions were made with a diluter which carried 
0.05 ml. of fluid from 1 well to the next to obtain two-fold 
dilutions. Washed sheep red blood cells at a concentration of 
0.7 percent in VBD were added to all wells in 0.025 ml. amounts 
with a dropper. The trays were covered with a plastic sealer, 
shaken gently on a mechanical shaker for 2 minutes and incubated 
overnight at 4°C. The HA tests were set up immediately after 
the cultures were harvested and the 2 percent bacterial suspen­
sions produced. The vaccine HA titers were determined utilizing 
the same procedure. 
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RESULTS 
Swine Experiments 
Bordetella rhinitis control by detection and elimination of 
infected swine. 
Experiment I Nasal secretions were collected on ster­
ile swabs and cultured on a selective modified MacConkey's 
agar medium for the isolation and identification of Bordetella 
bronchiseptica. Culture-positive breeding animals were culled. 
Switzer and Spear (1973) have demonstrated that pregnant sows 
negative for B. bronchiseptica nasal infection will usually 
wean litters negative for this organism. A pilot field control 
attempt was initiated in October, 1970 (Switzer, 1970a). The 
details of the detection and control method that evolved were 
as follows I (1) Nasal secretions were collected by means of 
nasal swabs from ^-to-lO-week-old pigs in a herd experiencing 
atrophic rhinitis and cultured to determine whether B. bronchi­
septica was present in the herd, A random sample of 25 pigs 
was considered adequate to determine the status of the herd. 
(2) If B. bronchiseptica was isolated from the pigs the follow­
ing criteria were evaluated before a control attempt was 
initiated: (a) the herd must be of sufficient genetic merit 
to justify the expense and effort of the control procedure; 
(b) the herd should have adequate facilities to enable the 
necessary isolation, cleanup, disinfection and fumigation; and 
(c) the producer should have a high degree of disease control 
awareness. (3) The entire breeding herd was subjected to nasal 
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swabbing. (4) All culture-positive animals were eliminated 
from the breeding herd as soon as they were detected. (5) Three 
negative nasal swab cultures were required for each breeding 
animal retained in the herd as a single nasal swab culture is 
estimated to be 75 to 90 percent accurate (Switzer and 
Farrington, 1972). (6) Animals that yield 3 or more cultures 
overgrown with contaminating organisms were eliminated provid­
ing the nasal swab sampling technique was satisfactory. (7) All 
bred sows and gilts were sampled an additional time within 2 
weeks prior to farrowing and only culture-negative animals 
entered the farrowing house, (8) The farrowing house(s), 
nursery(s), and growing-finishing buildings were emptied, 
cleaned, disinfected, fumigated and kept empty for 6 weeks if 
possible. (9) After all the above steps were satisfactorily 
completed, nasal swab samples from 1 (or more) 4-to-lO-week-old 
pig per litter from subsequent farrowings were utilized to mon­
itor the success of the control effort. (10) All additions to 
the herd were from a herd free of Bordetella rhinitis or must 
pass 3 negative nasal swab cultures. 
The rate of isolation of B, bronchiseptica from nasal swab 
specimens from swine breeding animals submitted to the Veteri­
nary Medical Research Institute, Iowa State University from 
October, 1970 to June, 1972, is presented in Table 1. 
74 
Table 1. Rate of isolation of Bordete11a bronchiseptica from 
swine nasal swab specimens from October, 1970 to 
June, 1972. 
Cultures 
Positive Negative Usable Overgrown 
Test (No. ) (^) (No. ) ()&) (No, ) (No.) (^) 
First 409 12 2,895 88 3,304 
Second 93 4 2,103 96 2,196 —  —  —  —  — —  — — — 
Third 40 3 1,430 97 1,470 — -  —  —  —  —  
Total 542 8 6,428 92 6,970 87 1,052 13 
Inspection of isolates of B. bronchiseptica from infected pigs 
does not allow an evaluation of their virulence. Therefore, 
recovery of B. bronchiseptica cannot be considered as a certain 
indication of an actual atrophic rhinitis problem in an 
infected herd. 
Because of the large number of swine producers and veteri­
narians who expressed interest in the nasal swab culture con­
trol procedure, many veterinarians established this technique 
in their practice laboratories. Several training sessions were 
held to facilitate this. In an attempt to evaluate progress 
during the first 18 months of the control effort, a question­
naire was mailed to the 66 veterinarians who had sent nasal 
swab samples to the Veterinary Medical Research Institute or 
who had established their own laboratories for the culturing of 
nasal swab specimens. Replies were received from 54 
veterinarians. The results are summarized in Figure 1, No 
attempt was made to select veterinarians for participation in 
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the testing program. 
Dear Dr. 
For over one year, the Bordetella bronchiseptica nasal swabbing 
program has been available as an experimental pilot project. 
We are now conducting an evaluation of field results in order 
to better define the potential of this program. We need your 
observations regarding this testing procedure. 
1. How many herds have you used this procedure on? 110 How 
many herds were positive for B. bronchiseptica? 80 How 
many had clinical rhinitis? 65 Total number of breeding 
animals involved? 8,995. 
2. Was there clinical improvement in those herds in which 
the bordetella carriers were removed from the breeding 
herd? Yes 23 No 6 
3. Was your client's reaction to the test favorable? 
Yes 3^ No 9 
4. Is swab collection too time consuming? Yes 3 No 41 . 
5. Do you have to wait too long for laboratory results? 
Yes_2 No 39 . 
6. Are too many breeding animals removed from the herd? 
Yes_j No 36 . 
7. Have you had complaints as to collection costs? 
Yes_8 No 37 . 
8. Has the program produced the desired results? 
Yes 13 No 8 Partially 21 . 
9. Is sulfonamide therapy effective in clinical B. bronchi­
septica situations in which you have used it? Yes 11 
No 7 Partially 28 . 
Figure 1. Summary of questionnaire response from 54 private 
practitioners participating in a Bordetella rhinitis 
control project. 
From October, 1970 to December, 1973, approximately 30,182 
nasal swab samples were submitted to the Veterinary Medical 
Research Institute, Iowa State University for the isolation and 
identification of B. bronchiseptica. These samples were 
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collected from 152 herds of which 107 were determined to be 
infected with B. bronchiseptica. Sulfamethazine sensitivity 
was determined for B. bronchiseptica isolates from 
76 herds. Forty of the 76 B. bronchiseptica isolates (53 per­
cent) were resistant at the 30mg./ml, level indicating a high 
degree of sulfamethazine resistance. Fourteen isolates (18 per­
cent) were sensitive at the 20 or 30mg./ml. level, but resis­
tant at the 5 and lOmg./ml. level indicating partial resistance 
to sulfamethazine. Twenty-two isolates (29 percent) were sensi­
tive to sulfamethazine at the 5, 10, 20 and 30mg./ml. levels 
indicating that they were sensitive to the drug. The data 
obtained from the 152 herds submitting swine nasal swabs to the 
Veterinary Medical Research Institute, Iowa State University is 
presented in Table 2, 
Table 2. Rate of Bordetella bronchiseptica isolation from 
swine nasal swab specimens, October, 1970, to 
December, 1973. Composite of all samples. 
Total Cultures 
Positive Negative Usable Overgrown 
(No.) (*) (No.) (9?) (No.) ifo) (No.) ifo) 
3,006 11.6 22,812 88.4 25,818 85.5 4,364 14.5 
Twenty-five herds utilizing the control procedure were 
followed in adequate detail to allow evaluation of the effi­
ciency of the procedure. Two criteria for success were used. 
The first was the production of swine free from clinical 
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atrophie rhinitis and the second was the production of swine 
free from B. bronchiseptica. These 25 herds comprised approxi­
mately 2,400 breeding animals and ranged in size from 20 to 300 
breeding animals. Twenty-four herds were culture-positive for 
B. bronchiseptica. Seventeen of these 24 herds were experienc­
ing clinical atrophic rhinitis at the initiation of the control 
effort. The culture-negative herd was established with sows 
that were culture-negative for B. bronchiseptica at the time of 
entry into the herd and the swine producer was interested in 
whether the negative status of the herd could be maintained 
through subsequent farrowings. 
Of the 17 herds with clinical atrophic rhinitis prior to 
the B. bronchiseptica control attempt, 13 (77 percent) subse­
quently produced pigs that did not have clinical evidence of 
atrophic rhinitis at weaning age. Nasal sampling of weaned 
pigs was completed in 12 of the 13 herds that eliminated clini­
cal atrophic rhinitis. Of these 12 herds, 10 (83 percent) pro­
duced pigs that were culture-negative for B. bronchiseptica at 
4-to-lO-weeks of age. 
Seven herds were initially culture-positive for B. bronchi­
septica. but were not experiencing clinical atrophic rhinitis. 
Five of these 7 herds (71 percent) produced pigs that were 
culture-negative for B. bronchiseptica at 4-to-lO-weeks of age. 
Of the 23 initial culture-positive herds that sampled 
weaning age pigs produced after the control effort, 15 (65 per­
cent) produced pigs that were culture-negative for 
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B. bronchiseptica at weaning age. The herd founded with B. 
bronchiseptica free breeding stock was found to be free of clin­
ical evidence of atrophic rhinitis and failed to yield B. bron-
chiseptica from nasal swab specimens from weaning age pigs for 
a 2 year period. 
Individual herd data of those 25 herds participating in 
the initial control effort is presented in Table 3. 
Natural clearance of a sulfamethazine resistant Bordetella 
bronchiseptica nasal infection. 
Experiment II Thirty naturally infected Bordetella 
rhinitis pigs averaging 12 weeks of age were secured from a 
production herd.^ These pigs had received a ration containing 
2 Aureo S-P 250 at the recommended level from approximately 3 to 
7 or 8 weeks of age. The pigs had mild to moderate clinical 
evidence of atrophic rhinitis at the time of procurement. They 
were placed in an isolated confinement area and fed a complete 
ration free of antibiotics or sulfonamides. The initial B. 
bronchiseptica infection was determined to be sulfamethazine 
resistant. The nasal swab culturing method was utilized for 
the isolation of B. bronchiseptica from the infected pigs. 
The natural clearance of the _B. bronchiseptica nasal infec­
tion and reestablishment of sulfamethazine sensitivity in the 
^Swine Teaching Herd, Department of Animal Science, Iowa 
State University, 
2 American Cyanamid Company, Princeton, New Jersey. 
Table 3. Bordetella rhinitis nasal swab culture control program herd data 
Herd 
Approximate 
Number in 
Breeding 
Herd 
B. bronchiseptica 
Posit ive/negative 
Clinical 
Evidence 
of 
Atrophic 
Rhinitis 
Turbinate 
Atrophy 
Observed at 
Slaughter 
or Necropsy 
1 80 Positive Severe Yes 
2 300 Positive Moderate Yes 
3 166 Positive Severe Yes 
4 65 Positive Severe Yes 
5 125 Positive Mild Yes 
6 30 Positive Moderate Yes 
7 20 Positive Moderate Yes 
8 200 Positive Severe Yes 
9 80 Positive Mild Yes 
10 60 Positive Moderate Yes 
11 122 Positive Mild No 
12 31 Positive None No 
13 92 Positive None No 
14 30 Positive None No 
15 
16 
17 
25 
Primary Lab 
Pigs Only 
41 
Positive 
Positive 
Positive 
None 
None 
None 
No 
No 
No 
18 220 Positive Severe Yes 
19 60 Positive Moderate Yes 
20 39 Positive None No 
21 180 Positive Moderate No 
22 60 Positive Severe Yes 
23 150 Positive Mild No 
24 200 Positive Mild — 
25 60 Negative None No 
Based on observations by herd owners and program veterinarians. 
Not determined. 
80 
Elimination of Production of 
bronchiseptica Clinical signs 4 to 10 week old 
Sulfamethazine of Atrophic Pigs free of 
Sensitivity Rhinitis _B. bronchiseptica 
Sensitive Yes No 
Resistant Yes Yes 
Resistant Yes Yes 
Partial Yes Yes 
Sensitive Yes Yes 
Resistant Yes Yes 
Sensitive Yes Yes 
Resistant Yes Yes 
Resistant Yes Yes 
Resistant Yes Yes 
Resistant Yes Yes 
—^ Not applicable Yes 
Resistant Not applicable Yes 
Resistant Not applicable Yes 
Resistant Not applicable No 
Sensitive Not applicable Yes 
Resistant Not applicable Yes 
— Yes No 
— Yes — 
Sensitive Not applicable No 
Resistant No No 
Sensitive No No 
Sensitive No No 
Partial No No 
— Not applicable Yes 
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population of infecting organisms is presented in Figure 2. 
The individual pig data is presented in Table 4. At least 1 
colony from each nasal culture of B. bronchiseptica isolate was 
tested for sulfamethazine sensitivity. Pigs negative for B, 
bronchiseptica on 2 consecutive samplings were considered as 
recovered from the infection. Six pigs became negative for B. 
bronchiseptica before the organism regained sulfamethazine 
sensitivity. 
Parenteral immunization of young pigs to produce resistance to 
Bordetella bronchiseptica nasal infections 
Experiment III This experiment tested the ability of a 
commercial canine origin B. bronchiseptica bacterin^ and labo­
ratory prepared immunizing agents to produce resistance to B. 
bronchiseptica nasal infections in a group of 4-to-8-week-old 
pigs. A partially purified B. bronchiseptica hemagglutinin 
extract was also administered to determine its ability to stim­
ulate respiratory tract resistance. The laboratory bacterins 
were prepared in a manner calculated to preserve maximum hemag­
glutinin (HA) titers. Vaccine HA titers are indicated in Table 
5. 
Thirty-two pigs, 4-to.8-weeks of age, were obtained from 
the Veterinary Medical Research Institute normal herd and from 
a Bordetella rhinitis free commercial herd. All pigs were 
determined to be negative for B. bronchiseptica nasal infection 
^Pitman-Moore, Inc., Washington Crossing, New Jersey, 
Bacterin Number 19-521. 
Figure 2. Natural clearance of Bordetella bronchiseptica nasal infection and 
reestablishment of sulfamethazine sensitivity in a group of thirty 
pigs 
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Table 4. Clearance of a natural Bordetella bronchiseptica nasal infection 
and reestablishment of sulfamethazine sensitivity 
1970 1971 1971 1971 
Date of 
Collection 11/18 12/7 1/11 2/11 3/8 4/9 4/22 
Pig Number 
D25-3 +R 
_c 
+S^ +S 
D24-6 +R +R +R +R - -
D22-2 +R +R +S30 +R OG® +s -
D-20-3 +R +R +S30 +S +S +s +s 
D-24-3 +R +R +R +R +8 +S20 +s 
D-21-10 +R +R +S30 - -
H28-4 +R +R +S±30 +5 - -
H-29-3 +R +R +S30 +R +S +s -
X21-5 +R +R +S30 - -
Y24-7 +R +R - +R +S +R +s 
X24-2 +R +R +S20 +R +s - -
X26-8 - +R +R +S30 +S - -
H-26-7 +R •rR +R - -
X22-5 +R +R +R +R +R +R +S30 
D26-5 +R +R +S20 +S +S +s +s 
D23-2 +R +R +S30 +S30 +S +S +S 
X27-4 OG +R +830 +R - -
Y23-11 +R +R +R +R +s - -
D21-6 - +R +R +S20 +R - -
H27-2 +R +R +R +5 - +S -
Y25-8 +R +R +R +R +R - -
D19-6 +R +R +R +S +R +S20 -
P24-7 +R +R +R +S20 - -
Y26-3 +R - +R +S20 - -
X30-5 +R +R - +S - +S20 +8 
P22-3 +R +R +S20 - +S - -
H31-3 +R OG +R - +S - -
H52-2 +R +R - +S +S +S -
H32-8 +R +R +S30 +S20 +S - -
CW2-7 +R +R +530 +R -
-
= Positive for bronchiseptica. 
= Resistant to 30 mg. level of Sulfamethazine. 
= Negative for B^. bronchiseptica. 
= Sensitive to 10 mg. level of Sulfamethazine. 
®0G = Overgrown sample not usable. 
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1971 1971 1971 1971 
5/3 5/17 6/1 6/8 6/15 6/25 7/9 7/21 8/6 8/20 
+S 
+S - +S20 OG +S30 
+S +S +S20 +S20 +S20 OG +S 
-* +S — OG — — — 
+S30 +S - +S20 OG OG 
+S30 +S +S +S20 +S +S20 +S +S20 
+S +S +S20 OG 
+R +S +S +S +S +S +S 
+S20 +S +R - +R +R +R +R 
+S Died 
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by nasal swab culturing. The pigs were placed in individual 
pens by litter and randomly selected for immunization or as non-
immunized controls. Four pigs died from stress during the 
trial. 
The pigs were vaccinated subcutaneously in the fold of the 
flank. Five pigs received D-1 strain sonicate, whole-cell, 
formalinized bacterin with adjuvant, 5 received D-1 strain whole-
cell, formalinized bacterin with adjuvant, and 4 pigs received 
55 strain whole-cell, formalinized bacterin with adjuvant. The 
D-1 and 55 strain bacterins were mixed in equal 1 milliliter 
volumes with Freund's incomplete adjuvant immediately prior to 
administration. Four pigs received B. bronchiseptica partially 
purified hemagglutinin extract without adjuvant (1 ml. dosage), 
7 received Pitman-Moore 19-521 bacterin without adjuvant (2 ml. 
dosage) and 7 pigs served as unvaccinated controls. Two doses 
of the immunizing agents were administered at a 1 week interval 
and the pigs were challenged with virulent B strain B. bronchi­
septica 18 days post-immunization. A booster dose of the immu­
nizing material was administered 7 weeks post-B strain challenge 
and 9 weeks post-immunization. Average PAST serum titers by 
vaccine group are presented in Table 5. A summary of the per­
formance of the vaccine groups during the experiment in regards 
to resistance to the B. bronchiseptica nasal challenge and the 
average B. bronchiseptica colony count is shown in Table 6. 
Eighteen snouts were examined for gross evidence of tur­
binate atrophy at the termination of the experiment. Gross 
Table 5. Average PAST serum titers by vaccine group 
Product 
3-28-72 
Prevaccination 
4—14—72 4—28—72 
1 Week Post- 2 Weeks 
1st Dose Post-2nd Dose 
6-16-72 
Pre-3rd 2 
Dose 
7-6-72 
Weeks Post-
3rd Dose 
8-21-72 
Termination 
D-1 Sonicate 
With Adjuvant 
(64)a 2 >4096 3686 >4096 >4096 >4096 
D-1 Whole-Cell 
With Adjuvant 
(128) 4 3379 >4096 >4096 >4096 >4096 
55 Whole-Cell 
With Adjuvant 
(64) 3 10 289 320 3088 1707 
Partially 
Purified 
B. bronchiseptica 
Hemagglutinin 
Extract 
(128) 1 2560 1536 271 1616 176 
Pitman-Moore 
19-521 
(0) 2 651 585 539 3547 860 
Nonvaccinated 
Controls 5 1 4 9 59 53 32 
1st 2nd JB. bronchlseptlca 3rd 
vaccination vaccination nasal challenge vaccination 
4-7-72 4-14-72 5-2-72 6-19-72 
^Vaccine hemagglutination titer. 
Table 6. Resistance of parenterally immunized pigs to bronchiseptica 
challenge 
3-28-72 5-9-72 5-18-72 
Product 
Pretrial 
Nasal 
Culture 
1 Week 
Post-
Challenge 
2 Weeks 
Post-
Challenge 
D-1 
Sonicate 
With 
Adjuvant 
0/5^ 
(0)^ 
2/4 
(3) 
4/4 
(12) 
D-1 
Whole-
Cell With 
Adjuvant 
0/5 
(0) 
3/5 
(6) 
4/5 
(96) 
55 
Whole-
Cell With 
Adjuvant 
0/4 
(0) 
2/4 
(39) 
3/4 
(.75) 
Partially 
Purified 
B. bronchisep­
tica Hemaeelu-
tinin Extract 
0/4 
(0) 
3/4 
(5) 
4/4 
(84) 
Pitman-
Moore 0/7 3/7 5/6 
19-521 (0) (36) (205) 
Non-
vaccinated 
Controls 
0/7 
(0) 
5/7 
(45) 
5/7 
(86) 
^hird dose vaccine administered 6-19-72. 
Number of pigs positive for bronchiseptica over number sampled . 
"^Number of pigs with turbinate atrophy at necropsy over number of 
l>igs examined. 
^Average B. bronchiseptica colony count. 
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5-31-72® 
4 Weeks 
Post-
Challenge 
7-5-72 
8 Weeks 
Post-
Challenge 
8-3-72 
10 Weeks 
Post-
Challenge 
8-21-72 
14 Weeks 
Post-r 
Challenge 
8-23-72 
Gross Evidence 
of Turbinate 
Atrophy at 
Necropsy 
4/4 3/4 1/4' 2/4 O/3C 
(7) (13) (.25) (10) 
5/5 4/5 2/5 3/4 0/4 
(75) (133) (20) (2) 
4/4 3/4 1/4 0/3 0/1 
(63) (13) (4) (0) 
4/4 3/4 2/4 2/4 1/3 
(115) (100) (225) (57) 
6/7 6/7 6/7 4/6 1/4 
(170) (227) (180) (30) 
5/7 7/7 6/7 6/7 2/3 
(230) (104) (102) (105) 
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turbinate atrophy was not observed in the pigs receiving labora­
tory produced B. bronchiseptica bacterins with adjuvant. Two of 3 
control pigs, 1 of 4 Pitman-Moore 19-521 immunized pigs and 1 
of 3 B. bronchiseptica partially purified hemagglutinin extract 
immunized pigs evidenced moderate to severe turbinate atrophy. 
At 10 weeks post-challenge, 4 out of 13 pigs vaccinated 
with laboratory experimental whole-cell bacterins were positive 
for B. bronchiseptica while 12 out of 14 pigs vaccinated with 
either Pitman-Moore 19-521 bacterin or unvaccinated controls 
were positive. At 14 weeks, the values for the two groups were 
5 for 11 and 10 for 13 respectively. The average colony counts 
were lower in the pigs immunized with the laboratory experi­
mental bacterins with adjuvant throughout the experiment. 
All pigs receiving bacterins containing Freund's incom­
plete adjuvant injected subcutaneously in the fold of the flank 
developed palpable, persistent enlargements at the site of 
injection. Bacterins administered without adjuvant or contain­
ing AB-65 adjuvant did not produce a comparable enlargement at 
the site of injection. 
Experiment IV Bordetella bronchiseptica strain D-1 
sonicate, whole-cell, formalinized bacterin with adjuvant con-
g 
taining approximately 2 x 10 B. bronchiseptica organisms per 
milliliter after sonication was administered to 3 and 6 week 
old pigs. A second group of 6-week-old pigs was immunized with 
the same bacterin without adjuvant. The bacterin contained a 
HA titer of 128 at the time of administration. 
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Thirty-three pigs, 3-to-6-weeks of age, were obtained from 
the Veterinary Medical Research Institute normal herd. The pigs 
were randomly assigned within the 3 or 6 week age groups to 
individual pens by vaccine groups. Two pigs died from stress 
during the experiment. 
The pigs were vaccinated subcutaneously in the fold of the 
flank. Five 3-week-old pigs and 7 6-week-old pigs received D-1 
strain, sonicate, whole-cell, formalinized bacterin (2 ml.) with 
adjuvant. The bacterin was mixed in equal volumes with Freund's 
incomplete adjuvant immediately prior to injection. Eight 6-
week-old pigs received D-1 strain, sonicate, whole-cell, formal­
inized bacterin without adjuvant (2 ml. dosage) and 5 3-week-
old and 8 6-week-old pigs served as nonvaccinated controls. 
Two doses of the vaccine were administered at a 10 day interval 
and the pigs were challenged with virulent B strain B. bronchi-
septica 14 days post-vaccination. Average PAST serum titers by 
age and vaccine groups are presented in Table 7. Resistance of 
the parenterally immunized pigs to B. bronchiseptica nasal chal­
lenge is summarized in Table 8. 
Thirty-one snouts were examined for gross evidence of tur­
binate atrophy at necropsy. Two 6-week-old control pigs and 
1 6-week-old D-1 sonicate without adjuvant immunized pigs had 
evidence of mild turbinate atrophy. Gross turbinate atrophy 
was not present in the 3 and 6-week-old pigs receiving the 
adjuvanted bacterin. 
At 2 weeks post-challenge, 4 out of 12 pigs vaccinated 
Table 7. Average PAST serum titers by vaccine group 
Age jf Pigs ^ 
Vaccinated/Product 
10-13-72 
Prevacclnation 
11-2-72 
1 Week Post-
Is t Dose 
11-16-72 
2 Weeks Post-
2nd Dose 
3-8-73 
Termination 
16 Weeks Post-
2nd Dose 
3 Week Old Pigs: 
Nonvaccina ted 
Controls 0.8 No Test 33 12 
3 Week Old Pigs: 
D-1 Sonicate With 
Adjuvant 1.6 640 3076 269 
6 Week Old Pigs: 
D-1 Sonicate With 
Adjuvant 0.5 >4096 3072 >4096 
6 Week Old Pigs ; 
D-1 Sonicate 
Without Adjuvant 0.8 2816 2286 1381 
6 Week Old Pigs: 
Nonvaccinated 
Controls 3 No Test 4.5 22 
1st Vaccination 2nd Vaccination bronchlseptica 
10-24-72 11-2-72 Nasal Challenge 
11-16-72 
^Vaccine hemagglutination titer 128 . 
Table 8. Resistance of parenterally immunized pigs to bronchiseptica 
challenge 
Age of Pigs 
Vaccinated/Product 
10-13-72 
Pretrial 
Nasal 
Culture 
12-1-72 
2 Weeks 
Post-
Challenge 
12-19-72 
4 Weeks 
Post-
Challenge 
3 Week Old Pigs: 
Nonvaccinated 
Controls 0/5* 5/5 4/5 
3 Week Old Pigs: 
D-1 Sonicate 
With Adjuvant 0/5 2/5 2/5 
6 Week Old Pigs: 
D-1 Sonicate 
With Adjuvant 0/7 2/7 4/7 
6 Week Old Pigs: 
D-1 Sonicate 
Without Adjuvant 0/8 5/8 4/8 
6 Week Old Pigs: 
Nonvaccinated 
Controls 0/7 8/8 8/8 
^Number of pigs positive for 2» bronchiseptica over number sampled. 
Number of pigs with turbinate atrophy at necropsy over number of 
pigs examined. 
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1-19-73 
8 Weeks 
Post-
Challenge 
2-23-73 
12 Weeks 
Post-
Challenge 
3-8-73 
15 Weeks 
Post-
Challenge 
Gross Evidence 
of Turbinate Atrophy 
at Necropsy 
2/4 2/4 1/4 0/4^ 
3/4 3/5 2/4 0/5 
4/7 4/7 3/7 0/7 
3/7 3/7 2/7 1/7 
6/8 4/8 3/8 2/8 
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with D-1 sonicate bacterin with adjuvant were culture-positive 
for B. bronchiseptica while 13 out of 13 controls were positive. 
This resistance waned until at 12 weeks post-challenge the fig­
ures for the 2 groups were 5 of 12 and 6 of 12 respectively. 
At l6 weeks post-immunization the average PAST serum titers 
were >4096 in the 6-week-old pigs and 269 in the 3-week-old 
pigs receiving D-1 sonicate bacterin with adjuvant. The 6-week-
old pigs receiving D-1 sonicate without adjuvant averaged I38I 
at this time. 
Experiment V Seven 5*to-6-week-old pigs were obtained 
from the Veterinary Medical Research Institute normal herd and 
were inoculated intranasally with virulent B strain B. bronchi-
septica. Nasal secretions of all 7 pigs were culture-positive 
for B. bronchiseptica 2 weeks post-challenge. Strain D-1 soni­
cate, whole-cell, formalinized bacterin containing approximately 
2 X 10^ organisms per milliliter was administered subcutaneously 
3 weeks post-challenge to 4 of the pigs. The first dose (2 ml.) 
was given without adjuvant and the second dose (2ml.) given 7 
days later contained an equal volume of Freund's incomplete 
adjuvant. At 3 weeks post-vaccination 4 of 4 vaccinates and 2 
of 3 controls were culture-positive for B. bronchiseptica. At 
15 weeks post-vaccination 1 of 4 vaccinates and 2 of 3 controls 
were culture-positive for B. bronchiseptica. The average PAST 
serum titer of vaccinated pigs was 2688 2 weeks post-vaccina­
tion and 2112 I5 weeks post-vaccination. Mild gross turbinate 
atrophy was observed at necropsy in 1 vaccinate while 3 
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vaccinated swine had normal turbinates. Two control swine had 
normal turbinates and 1 had mild turbinate atrophy. 
Experiment VI Seven 6-week-old pigs were obtained from 
the Veterinary Medical Research Institute normal herd. Strain 
D-1 sonicate, whole-cell, formalinized bacterin with AB-65 
1 8 
adjuvant containing approximately 11 x 10 organisms per milli­
liter was subcutaneously administered to the ? pigs. No control 
swine were utilized in this experiment. Equal volumes of AB-65 
adjuvant and D-1 sonicate bacterin were mixed and injected in 
2 ml. dosages. 
The pigs were immunized with 2 doses of the immunizing 
agent JO days apart with a virulent B strain B. bronchiseptica 
nasal challenge midpoint between vaccinations. 
Nasal secretions of 6 of 7 pigs were culture-positive for 
B. bronchiseptica 2 weeks post-challenge and 0 of 7 were cul-
ture-positive by 9 to 12 weeks post-challenge. The average 
PAST serum titer of the pigs was 2962 3 weeks post-vaccination 
and 1351 at I6 weeks post-vaccination. Two of 7 pigs had slight 
malformation of the ventral scroll of the ventral turbinates 
while 5 had normal nasal cavities when examined at necropsy. 
Intranasal vaccination of young pigs to produce resistance to 
Bordetella bronchiseptica nasal infections 
Experiment VII The ability of live, low-virulence 55 
^Armour-Baldwin Laboratories, Omaha, Nebraska. 
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strain B. bronchiseptica intranasal vaccination to produce nasal 
resistance to subsequent challenge with swine virulent B strain 
B. bronchiseptica was tested. The nasal persistence of 55 
strain infection was also evaluated. 
Twelve pigs, 4-to-8-weeks of age, were obtained from the 
Veterinary Medical Research Institute normal herd and a Borde-
tella rhinitis free commercial herd. All pigs were culture-
negative for B. bronchiseptica. The pigs were selected into 2 
groups and housed in individual isolation units. 
Six pigs received 3 doses over a 4 day period of live, low-
virulence 55 strain intranasal vaccine at 7 weeks of age and 7 
pigs served as nonvaccinated controls. All pigs were challenged 
with virulent B strain B. bronchiseptica 3 weeks post-intranasal 
vaccination. 
Strain 55 was not detected by the nasal swab culture 
method in the nasal secretions of the vaccinated pigs 2 weeks 
post-intranasal vaccination. 
A summary of the incidence of B. bronchiseptica in the 
nasal secretions of the B strain challenged pigs is presented 
in Table 9. At 3 weeks post-B strain challenge 0 of 6 vacci­
nates and 5 of 7 control pigs were culture-positive for B. 
bronchiseptica. At 4 weeks post-B strain challenge the nasal 
secretions of 3 of 6 vaccinated pigs were culture-positive for 
B. bronchiseptica with an average colony count of 6 organisms 
per culture plate. The 8 week termination figures were 0 of 6 
and 7 of 7 respectively. The average termination PAST serum 
Table 9. Incidence of Bordetella bronchiseptica in the nasal secretions of swine after intranasal 
installation of live, low-virulence 55 strain bronchiseptica vaccine and subsequent 
challenge with virulent B strain !B. bronchiseptica 
Number of swine culture-positive for 
B. bronchiseptica over number sampled 
Number of 
Swine 
Weeks after virulent B strain 
B. bronchiseptica challenge 
Gross evidence 
of turbinate 
Atrophy 
at necropsy Swine/Product Pretrial 3 4 6 8 
4 to 8-week-old 
Pigs, live, low-
Virulence 55 
Strain Intranasal 
Vaccination 
6 0/6 0/6 3/6 0/6 0/6 0/6* 
4 to 8-week-old 
Pigs. Non-
Vaccinated 
Controls 
7 0/7 5/7 6/7 6/7 7/7 2/3 
dumber of pigs showing gross turbinate atrophy over number necropsied . 
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titer was 39 for the vaccinated pigs and 53 for the nonvacci-
nated controls. At necropsy, gross examination revealed all 
intranasally immunized pigs had normal nasal turbinates while 
2 of 3 controls examined had moderate to severe turbinate 
atrophy. 
Experiment VIII The ability of live, low-virulence 
strain 55 B. bronchiseptica intranasal vaccination to produce 
nasal resistance to subsequent challenge with B strain swine 
virulent B. Bronchiseptica was reevaluated. In addition, ster­
ile filtrates from 55 strain B, bronchiseptica 24 hour TPB cul­
tures were instilled intranasally to determine their protective 
ability. The nasal persistence of 55 strain was also evaluated. 
Fifteen pigs, 3-to-4-weeks of age, were obtained from the 
Veterinary Medical Research Institute normal herd. The pigs 
were randomly selected into 3 groups and placed in individual 
isolation units. 
Six pigs received 3 doses over a 4- day period of live, 
low-virulence 55 strain B. bronchiseptica intranasal vaccine, 
5 pigs received 3 doses over a 4 day period of 55 strain TPB 
culture sterile filtrate and k pigs served as unvaccinated con­
trols. All pigs were challenged with swine virulent B strain 
2 weeks post-intranasal immunization. The 55 strain B. bron­
chiseptica was not detected on nasal swab culture 6 days post-
vaccination. The pigs were 4 to 5 weeks of age at the time of 
55 strain vaccination and 6 to 7 weeks of age at the time of 
B strain challenge. 
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A summary of the incidence of B. bronchiseptica in the 
nasal secretions of the B strain challenged pigs during the 
first 12 weeks of the experiment is presented in Table 10. At 
2 weeks post-B strain challenge 0 of 4 live, 55 strain vacci­
nates, 5 of 6 55 strain sterile TPB culture filtrate vaccinates 
and 4 of 4 control pigs were culture-positive for B, bronchisep­
tica. The 12 week figures were 0 of 5, 1 of 6 and 1 of 4 
At 8 weeks and 1? weeks post-first B strain challenge, the 
live 55 strain intranasally vaccinated pigs were rechallenged 
with B strain. Bordetella bronchiseptica was not detected in 
the nasal secretions of live, low-virulence 55 strain intrana­
sally vaccinated pigs for the entire 19 week sampling period. 
The average termination PAST serum titer was 38 for the 
live 55 strain vaccinates, 8 for the 55 strain TPB sterile fil­
trate vaccinates and 13 for the nonvaccinated controls. At 
necropsy gross examination revealed all intranasally vaccinated 
pigs had normal turbinate structures while 3 of 4 controls had 
mild turbinate atrophy. 
Effects of colostral antibodies and intranasal immunization on 
resistance to Bordetella bronchiseptica nasal infection and tur­
binate atrophy. 
Experiment IX Three pregnant sows were obtained from 
a Bordetella rhinitis negative commercial herd. The sows were 
culture-negative for B. bronchiseptica and were housed in indi­
vidual isolation units. 
Two of the sows (numbers 1 and 2) were immunized with 
Table 10. Incidence of Bordetella bronchlseptica in the nasal secretions of swine after intranasal 
installation of live, low-virulence 55 strain _B. bronchlseptica vaccine or 55 strain TPB 
culture sterile filtrate and subsequent challenge with virulent B strain bronchlseptica 
Number of swine positive for 
bronchlseptica over number sampled 
Number 
of 
Swine Pretrial 
Weeks after virulent B strain 
B^. bronchlseptica challenge 
Gross Evidence 
of Turbinate 
Atrophy at 
Necropsy Swine/Product 2 4 6 8 12 
5-week-old pigs. 
Live, low-virulence 
55 strain 5 0/5 0/4 0/5 0/5 0/5 0/5 0/4 
Intranasal 
Vaccination 
5-week-old pigs. 
55 strain TPB 
Culture sterile 6 0/6 5/6 5/6 1/6 1/6 1/6 0/6 
Filtrate intranasal 
Vaccination 
4 to 5-week-old 
pigs. Non-
Vaccinated 
Controls 
4 0/4 4/4 3/4 3/4 2/4 1/4 3/4 
*One sample was not interpretable due to overgrowth with contaminating organisms. 
^Number of pigs with turbinate atrophy at necropsy over number of pigs examined . 
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strain D-1 sonicate, whole-cell bacterin with adjuvant contain-
g 
ing approximately 8 x 10 organisms per milliliter. The sows 
received 2 subcutaneous doses of the bacterin 7 days apart, 24 
days (in the case of number 1) and 32 days (in the case of num­
ber 2) prior to farrowing. The bacterin was incorporated with 
Freund's incomplete adjuvant for the first dose and AB-65 adju­
vant for the second dose. One sow (number 3)» served as a non-
immunized control. Sows 1 and 2 developed PAST serum titers of 
>4096 20 days post-immunization. This was 4 days prefarrowing 
for sow 1 and 12 days prefarrowing for sow 2. At 52 days post-
immunization and 28 days post-farrowing sow 1 had a PAST serum 
titer of >4096. Litters farrowed by sows 1 and 2 had PAST serum 
titers that averaged 1283 and 156 respectively at 3 weeks of 
age. The litter farrowed from sow 3 had an average PAST serum 
titer of 11 at 6 weeks of age. 
The pigs from sow 2 were accidently killed at 22 days of 
age due to a malfunction of the isolation building. Litters 
from sows 1 and 3 were weaned at 5 weeks of age. 
Pigs farrowed by sows 1 and 3 were administered 3 doses of 
live, low-virulence 55 strain B. bronchiseptica intranasal vac­
cine during the first 5 days of life. The pigs were challenged 
with swine virulent B strain B. bronchiseptica 12 to 14 days 
after the last intranasal immunization. Results of nasal swab 
culturing and necropsy observation of these challenged pigs is 
presented in Table 11. 
One of 10 intranasally immunized pigs nursing sow 1 was 
Table 11. Resistance to Bordetella bronchlseptlca nasal infection in live, low-virulence 55 strain 
bronchlseptlca intranasally vaccinated newborn pigs nursing immunized and 
nonimmunlzed sows 
Immunization 
State of sows/ 
Number of pigs 
Age of pigs 
at B strain 
Challenge 
Number of swine culture-positive for 
JB. bronchiseptica over number sampled 
at various times after B strain challenge 
2 weeks 4 weeks 6 weeks 8 weeks 12 weeks 
Gross 
Evidence 
of turbinate 
Atrophy at 
Necropsy 
Immunized 
(Sow 1) 19 1/9* 0/10 1/11 Not 0/8 
11 pigs days Sampled 
H 
(Sow 3) 16 2/7 3/7 5/9 6/8 . 4/8 0/9^ & 
Nonimraunized 
9 pigs days 
^ig number 479 was culture-positive at the 2 week and 6 week sampling period with an average 
colony count of 5. 
^The experiment involving the litter from sow 1 was terminated after the negative 12 week nasal 
swab culturing and the pigs assigned to other research . 
c. 
'Number of pigs showing gross turbinate atrophy over number necropsied 
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culture-positive subsequent to B strain challenge. Intranasally 
immunized pigs nursing sow 3 (nonimmune colostral control) were 
all culture-positive for B. bronchiseptica at some time during 
the experiment. At necropsy pigs from sow 3 had an average PAST 
serum titer of 9. B. bronchiseptica was found in the ethmoid 
turbinates of 4 of 7 pigs and all turbinates were grossly 
normal. 
Experiment X Six bred gilts were obtained from a 
Bordetella rhinitis free purebred SPF herd. The gilts were 
culture-negative for B, bronchiseptica and were housed in indi­
vidual isolation units. 
Three gilts (numbers 1, 2, and 3) were immunized with 2 
3 ml. doses of strain D-1 sonicate, whole-cell bacterin with 
AB-65 adjuvant. The doses of bacterin were administered 12 days 
apart approximately 4 to 6 weeks prior to farrowing, the bac-
o 
terin contained approximately 1 x 10 organisms per milliliter 
and was administered subcutaneously with equal volumes of 
adjuvant. Three gilts (numbers 4, 5i and 6) served as nonimmu­
nized controls. 
The immunized gilts developed high titers of agglutinating 
antibody as indicated in Table 12. The PAST serum titers 
observed in the pigs nursing these gilts is also presented in 
Table 12. 
Pigs nursing gilts 1, 2, 5 and 6 were intranasally vacci­
nated with live, low-virulence 55 strain B. bronchiseptica 
according to the schedule presented in Tables 13 and 14. Pigs 
Table 12. PAST serum titers in experimental gilts and their offspring 
Litter Litter 
Gilt Pest-farrowing Termination 
Gilt Immunization Prefarrowing Average Average 
Number Status PAST PAST/age PAST/age 
1024 50 33 
1 4 days prefarrowing 3-5 weeks 14-16 weeks 
(22 days post-immunization) (8 pigs) (9 pigs) 
Immunization 
With 2 doses of >4096 19 13 
2 D-1 sonicate 1 day prefarrowing 4 weeks 16 weeks 
Bacterin with (30 days post-immunization) (6 pigs) (8 pigs) 
Adjuvant 
>4096 176 256 116 
3 10 days prefarrowing 5 days 5 weeks 16 weeks 
(30 days post-immunization) (4 pigs) (4 pigs) 
2 26 
4 128 7 weeks 20 weeks 
(3 pigs) (3 pigs) 
2 35 
5 Noniimnunlzed 256 4 weeks 20 weeks 
(7 pigs) (7 pigs) 
<1 17 
6 128 4 weeks 14-16 weeks 
(10 pigs) (10 pigs) 
Table 13. Resistance to Bordetella bronchiseptlca nasal infection in live, low-virulence 55 strain 
JB. bronchiseptica intranasally vaccinated pigs nursing Immunized dams 
Gilt number/ 
Age of pigs at 
Intranasal 
Vaccination/ 
Number of pigs 
Age of pigs 
at B strain 
Challenge 
Number of swine culture-positive for 
bronchiseptica over number sampled 
at various times after B strain challenge 
2 weeks 6 weeks 10 weeks 14 weeks 16 weeks 
Gross 
Evidence 
of turbinate 
Atrophy at 
Necropsy 
Gilt 1 
2, 3, 35 days, 45 2/4 4/4 3/4 2/4 Not 0/4* 
4 pigs Days Sampled 
Gilt 1 
2, 3, 21 days, 
5 pigs 
30 
Days 
2/5 2/5 1/5 5/5 3/4 o/s" 
Gilt 2 
2, 3 days, 
8 pigs 
21 
Days 
0/8 1/7 2/8 3/8 3/6 o
 o
 
Gilt 3, 
Pigs not 
Immunized 
4 pigs 
5 
Days 
2/4 3/4 4/4 4/4 4/4 1/4 
dumber of pigs showing gross turbinate atrophy over number necropsied. 
Five pigs showed slight malformation of the ventral scroll of the ventral turbinate. 
One pig showed slight malformation of the ventral scroll of the ventral turbinate. 
Table 14. Resistance to Bordetella bronchiseptica nasal infection in live, low-virulence 55 strain 
bronchiseptica intranasally vaccinated pigs nursing nonimmunized dams 
Number of swine culture-positive for 
Gilt number/ bronchiseptica over number sampled Gross 
Age of pigs at at various times after B strain challenge Evidence 
Intranasal 
Vaccination/ 
Number of pigs 
Age of pigs 
at B strain 
Challenge 2 weeks 
4 to 6 
weeks 
8 to 10 
weeks 
12 to 14 
weeks 
16 to 20 
weeks 
of turbinate 
Atrophy at 
Necropsy 
Gilt 6 
2, 3, 35 days, 
5 pigs 
45 
Days 
0/5 1/5 0/5 0/5 Not 
Sampled 
1/5* 
Gilt 6 
2, 3, 23 Days, 
5 pigs 
35 
Days 
3/4 3/4 1/5 2/5 1/5 0/5^ 
Gilt 5 
2, 3 Days, 
7 pigs 
21 
Days 
0/7 1/7 1/7 2/7 1/7 0/7= 
Gilt 4 
Pigs not 
Immunized, 
3 pigs 
21 
Days 
3/3 3/3 2/3 3/3 3/3 2/3 
^Number of pigs showing gross turbinate atrophy over number necropsied. 
^One pig showed slight malformation of the ventral scroll of the ventral turbinate. 
^Three pigs showed slight malformation of the ventral scroll of the ventral turbinate. 
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farrowed by gilts 3 and 4 were not intranasally immunized. All 
pigs were challenged with swine virulent B strain B, bronchisep-
tica according to the schedule presented in Tables 13 and 14. 
The recovery of B. bronchiseptica from nasal swabs collected 
from these pigs and the production of turbinate atrophy in 
groups of the pigs is also presented in Tables 13 and 14, The 
pigs were weaned at 21 days of age and moved to individual iso­
lation units or to the Veterinary Medical Research Institute 
hilltop swine rearing unit. Some unplanned mixing of the dif­
ferent groups took place at the hilltop unit. 
Inoculation of three-week-old pigs with eleventh serial embrv-
onating hens egg passage of 55 strain Bordetella bronchiseptica. 
Experiment XI The eleventh serial passage of 35 strain 
B. bronchiseptica in 6-to-8-day-old embryonated hens eggs was 
used as challenge inoculum in susceptible swine to determine if 
an increase in swine virulence had occurred. Embryo mortality 
caused by 11 back passages of 55 strain B. bronchiseptica is 
summarized in Table 15. Eleventh passage 55 strain B. bronchi­
septica egg yolk inoculum was administered in 2 doses 2 days 
apart to 4 3-week-old pigs. The pigs were obtained from the 
Veterinary Medical Research Institute normal herd and housed 
in an individual isolation unit. Strain 55 was not detected 
in the nasal secretions of the 4 pigs 1 or 2 weeks post-
challenge . 
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Table 15. Serial passage of 55 strain bronchiseptica in 6 to 8 day old 
chicken embryos 
Number of dead embryos/total embryonated hens eggs 
Passage 
Number 24 hours 48 hours 72 hours 96 ho 
1 0/10 0/10 10/10 
2 2*/10 6/10 10/10 
3 0/10 0/10 10/10 
4 0/10 0/10 10/10 
5 1/10 1/10 10/10 
6 0/10 0/10 10/10 
7 2/10 5/10 10/10 
8 0/10 0/10 10/10 
9" 1/18 1/18 1/18 5/18 
10 0/18 0/18 0/18 0/18' 
11 0/10 0/10 0/10 5/10 
^The early embryonic mortality was ascribed to inoculation trauma. 
staphylococcus contaminant occurred in the ninth passage. The eighth 
embryonating hens egg passage was plated onto blood agar. An individual 
colony of 55 strain bronchiseptica was picked into three milliliters of 
TPS, incubated for 24 hours and used to inoculate the 9th passage. 
^The embryos were moribund but not dead . 
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The pigs were subsequently challenged with B strain B. 
bronchiseptica 3 weeks post-eleventh passage 55 strain challenge. 
Three weeks post-B strain challenge nasal secretions of 3 of 4 
pigs were culture-positive for B, bronchiseptica. At 5 weeks 
post-B strain challenge 0 of 4 pigs were culture-positive for 
B. bronchiseptica. At necropsy all 4 pigs had grossly normal 
turbinates. The ethmoid turbinates were culture-negative for 
B. bronchiseptica at the time of necropsy. 
Morphology of 55 and B Strain Compared with 
Previous Characterizations of Bordetella bronchiseptica 
Bordetella bronchiseptica is a gram-negative, short cocco-
bacillary rod motile by means of peritrichous flagella (Breed 
et al.. 1957). Richter and Kress (196?) found considerable var­
iation in the size of B. bronchiseptica grown on solid media. 
Cells measured from 3.0 by 0.5» 1.0 by 0.5 to 0.5 by 0.4 micro­
meters respectively. They found that the fine structure of 
B. bronchiseptica closely resembled that of other gram-negative 
bacteria. The organism was said to possess* (1) a cell wall of 
5 or more layers, (2) a trilaminar cell membrane, (3) abundant 
ribosomes embedded in the cytoplasmic matrix, (4) nucleoidal 
material consisting of dense bodies and fibrils, and (5) peri­
trichous flagella composed of interlacing strands. 
Since 55 strain B. bronchiseptica has been demonstrated 
to have some potential as a live intranasal vaccine, the elec­
tron microscope was used to further characterize this organism. 
Ill 
strain B B. bronchiseptica (a swine virulent strain) was uti­
lized as a control organism. 
An average sized (0.4 x 0.7 micrometer), single coccoba-
cillary 55 strain cell is pictured in Figure 3. This bacterium 
shows the convoluted surface typical of gram-negative bacteria. 
Richter and Kress (196?) described the surface of B. bronchisep­
tica as wrinkled, with lobules up to several hundred angstroms 
in width that are separated by furrows about 100 to 200 ang­
stroms in width. 
Filamentous organisms were regularly observed in nega­
tively stained 55 strain TPB cultures. A representative 55 
strain filamentous form showing the typical convoluted surface 
is shown in Figure 4. 
Cell division with asymmetry in the size of the daughter 
cells was commonly observed in 55 and B strain cultures. Asym­
metrical division showing daughter 55 strain cells with the 
membranous tubular connection still intact is pictured in 
Figure 5. 
A longitudinal cross-section of B strain is shown in 
Figure 6, Retraction of the bacterial cell membrane and cyto­
plasm from the cell wall is evident, Richter and Kress (196?) 
state that retraction of the cell wall from the cell membrane 
may not always be an artifact, but may indicate impending disin­
tegration of the cell wall. The nuclear zones in this electron 
micrograph are quite distinct. The nucleoplasm is whorled and 
the cell wall is furrowed. 
Figure 3. Negatively stained 55 strain Bordetella bronchisep-
tica. Forty-eight hour blood agar culture. Note 
the convoluted surface. Cellular dimensions approx­
imately 0.4- X 0.72 micrometers. X98, 000. Bar 
equals 0.1 micrometer. 
Figure 4. Negatively stained 55 strain Bordetella bronchisep-
tica. Twenty-four hour tryptose phosphate broth 
culture. Representative filamentous form. Many 
organisms were longer or shorter in the same culture. 
X17,000. Bar equals 1.0 micrometer. 

Figure 5. Negatively stained 55 strain Bordetella bronchisep-
tica. Forty-eight hour blood agar culture. Asym­
metrical division with membranous tubular connec­
tion (arrow). X85,000. Bar equals 0.1 micrometer. 
Figure 6. Longitudinal cross-section of B strain Bordetella 
bronchiseptica. Forty-eight hour tryptose phos­
phate broth culture. Uranyl acetate and lead 
citrate stain. Note the furrowed cell wall. 
Appearance of the nucleoplasms is whorled and 
rarefied (N). Retraction (shrinkage) of the bac­
terial cell membrane and cytoplasm from the cell 
wall is evident (arrow). X90,000. Bar equals 
0.1 micrometer. 
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A membranous lamellar structure^ oriented perpendicular 
to the cytoplasmic membrane is shown in Figures 7 and 8, Due 
to its central location and close association with the bacterial 
nucleoplasm the structure may be of mesosomal origin. Richter 
and Kress (196?) questioned whether previously described intra-
cytoplasmic membranes were not actually mesosomes. 
In cross section the cell wall has a multilaminar struc­
ture. Three osmophilic layers alternate with less opaque 
layers (Richter and Kress, 196?). Morse and Morse (1970) stated 
that the cell wall of Bordetella pertussis, in common with other 
gram-negative cells, is composed of 5 layers. The outer 
3 layers were said to have the appearance of a unit 
membrane. The outer unit membrane is separated from a deeper, 
dense, mucopeptide layer by a less dense layer. A thin section 
of 55 strain illustrating the multilaminar nature of the cell 
wall is presented in Figure 9. Three dense layers separated 
by 2 less dense layers are seen. Richter and Kress (1967) 
determined that in perpendicular cross sections of fixed, embed­
ded B. bronchiseptica, cell wall thickness was 100 to 200 
angstroms. 
Uniformly distributed fibrillar appendages^ were observed 
on negatively stained 55 and B strain cells from 24 hour blood 
agar cultures (Figures 10 and 11). These appendages were 
^A. E. Ritchie, National Animal Disease Laboratory, 
Ames, Iowa. 
Figure 7. Longitudinal cross-section of B strain Bordetella 
bronchiseptica. Forty-eight hour tryptose phos­
phate broth culture. Uranyl acetate and lead 
citrate stain. Note membranous lamellar structure 
oriented perpendicular to the cytoplasmic membrane 
(arrow) and polar granular inclusion (I). Cellu­
lar dimensions approximately 0.4 x 1.0 micrometers. 
X120,000. Bar equals 0.1 micrometer. 
Figure 8. Perpendicular cross-section of B strain Bordetella 
bronchiseptica. Forty-eight hour tryptose phos­
phate broth culture. Uranyl acetate and lead 
citrate stain. Note membranous lamellar structure 
(arrow) and apparent retraction of the bacterial 
cell membrane and cytoplasm from the cell wall, 
X210,000, Bar equals 0.1 micrometer. 
Figure 9. Perpendicular cross-section of 55 strain Bordetella 
bronchiseptica. Forty-eight hour tryptose phos­
phate broth culture, Uranyl acetate and lead 
citrate stain. Note raultilaminar structure of cell 
wall (arrow). Cell wall thickness approximately 
l60 angstroms, X176,000. 
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estimated to be less than 3 nanometers in diameter.^ Morse 
and Morse (1970) described a filametous particle found in the 
supernatant fluids of phase I Bordetella pertussis. These fila­
ments had a diameter of approximately 2 nanometers and ranged 
in length from 40 to 70 nanometers. They also observed these 
filaments in cultures of B, bronchiseptica and Bordetella para­
pertussis. The filaments were seen attached to the bacterial 
cell during the early stages of growth and numerous free fila­
ments were found in the culture medium during the latter part of 
log phase growth. Morse and Morse (1970) concluded that the 
filaments were not readily comparable with any previously 
described bacterial structure. 
The fibrillar appendages present on the 55 strain cell 
surface were considerably fewer in number than on the B strain 
cells. Figure 12 shows a portion of the cell wall of a B strain 
cell with the fibrillar appendages apparently emanating from the 
cell surface. 
Labaw and Mosley (1955) reported that the flagella of B. 
bronchiseptica had the external contour of a counter-clockwise 
or left-handed triple helix. The average periodicity along the 
length of the flagella was measured as 190 angstroms with an 
average flagellar diameter of 139 angstroms. They estimated 
that the average length of B. bronchiseptica flagella was 17 
^A. E. Ritchie, National Animal Disease Laboratory, 
Ames, Iowa 
Figure 10. Negatively stained B strain Bordetella bronchisep-
tica. Twenty-four hour blood agar culture. Note 
uniformly distributed fibrillar appendages (arrow). 
Cellular dimensions approximately 0.6 x 0.9 micro­
meters with fibrillar appendages less than 3.0 
nanometers in diameter. X114,000. Bar equals 0.1 
micrometer. 
Figure 11. Negatively stained 55 strain Bordetella bronchisep-
tica. Twenty-four hour blood agar culture. Fib­
rillar appendages (arrow) present but considerably 
fewer in number than in Figure 11. Cellular dimen­
sions approximately 0.6 x 1.0 micrometers. 
X88,000. Bar equals 0.1 micrometer. 
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micrometers. Richter and Kress (196?), however, found the fla-
gellum to appear as braids with interlacing strands. They were 
unable to determine the exact number of strands, but were able 
to observe profiles of 5 to 6 strands per flagellum. The 
thickness was determined to be generally between 180 and 200 
angstroms. A portion of a 55 strain flagellum is pictured in 
Figure 13. A 55 strain flagellated cell showing the hooked 
portion of a flagellum as it exits from the cell surface is 
shown in Figure 14. 
A cellular surface protrusion of unknown significance is 
shown in Figures 15 and l6. This structure was frequently 
encountered in a negatively stained 55 strain 48 hour TPB 
culture. It was not observed in a similar B strain culture. 
The dimensions of the protrusion are approximately 0.25 x 0,25 
micrometer. It is not evident by negative staining techniques 
whether the structure is of cytoplasmic, cell membrane or cell 
surface origin. 
Biological Comparison of 55, D-1 and 
B Strain Bordetella bronchiseptica 
Three strains of B. bronchiseptica were compared in bio­
logical and hemagglutination tests. All 3 strains (55, D-1 
and B) are small gram-negative rods. The comparisons between 
55, D-1 and B strain B. bronchiseptica are presented in Table l6. 
Strain 55 differed from D-1 and B strains in a number of 
significant ways. These were as followsi (1) Strain 55 
colonies on modified MacConkey's agar medium without Furaltadone 
Figure 12. Negatively stained B strain Bordetella bronchisep-
tica. Enlargement of portion of Figure 11 show­
ing fibrillar appendages (arrow). X195f000. Bar 
equals 0.1 micrometer. 
Figure 13. Negatively stained 55 strain Bordetella bronchisep-
tica. Twenty-four hour blood agar culture. Part 
of flagellum of approximately 135 angstrom diameter. 
A multistranded appearance is suggested. X230,000. 
Figure 14 . Negatively stained 55 strain Bordetella bronchisep-
tica. Twenty-four hour blood agar culture. Fla­
gellated cell showing the hooked portion at the 
point of a flagellum*s exit from the cell surface 
(arrow). X104,000. Bar equals 0.1 micrometer. 
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Figure 15. Negatively stained 55 strain Bordetella bronchisep-
tica from 48 hour culture in tryptose phosphate 
broth. Circular surface protrusion of unknown sig­
nificance frequently encountered in this culture, 
X130,000. Bar equals 0.1 micrometer. 
Figure l6. Negatively stained 55 strain Bordetella bronchisep-
tica from 48 hour culture in tryptose phosphate 
broth. Enlargement of circular surface protrusion 
present in another cell in the same culture as 
Figure l6. Dimensions of structure approximately 
0.25 X 0.25 micrometer. X190,000. Bar equals 
0.1 micrometer. 
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incubated at 37°C had a "lacy" margin. Strains D-1 and B colony 
margins were undulate. The colony diameter at 48 hours was 
approximately 1 ml. with colonies up to several millimeters in 
diameter present after prolonged incubation. All 3 strains 
formed colonies on 5 percent horse blood agar that were circu­
lar, smooth, opaque, and homogeneous with an entire edge. The 
colony size and morphology of the B, bronchiseptica strains 
varied greatly depending on the concentration of organisms on 
the culture plate, hours (days) of incubation at 37°C or room 
temperature and the relative humidity under which the culture 
plates were maintained. Aged colonies on modified MacConkey's 
agar without Furaltadone were characterized by central collapse 
of the colony and pronounced undulating rays from the cell mar­
gin giving the colony a "wagon wheel" shape. (2) Strains D-1 
and B were motile while 55 strain was often nonmotile when 
examined by the hanging drop method. (3) Strain 55 was sensi­
tive to Furaltadone at the 0.02 mg./ml, concentration in the 
modified MacConkey's medium while D-1 and B strain were not. 
(4) Strain 55 gave a slow and weak positive reaction (<24 hours) 
on Simmon's citrate agar slants while D-1 and B strains were 
strongly positive at 18 to 24 hours. (5) Strain 55 had the 
highest hemagglutinating titer among the 3 strains. Addition­
ally, 55 strain, and D-1 strain as reported by Ross et al. 
(1967) have been shown to be incapable of causing turbinate 
atrophy in swine, while B strain (Ross et al,, 1963a) has been 
used to produce turbinate atrophy in experimental swine. 
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Table 16. Comparison of 55, D-1 and B strain Bordetella bronchiseptlca 
Test 
6th passage 
55 strain 
9th passage 
D-1 strain 
8th passage 
B strain 
Colony morphology 
Circular, margin 
Lacy, smooth. 
Homogeneous 
Circular, margin 
Undulate, smooth 
Homogeneous 
Circular, margin 
Undulate, smooth 
Homogeneous 
Lactose broth Alkaline Alkaline Alkaline 
Dextrose broth Alkaline Alkaline Alkaline 
Urea agar slant + 2-12 hours + 2-12 hours + 2-12 hours 
Simmon's citrate 
Agar slant Weak + + + 
Litmus milk 
Alkaline 
48 hours 
Alkaline 
48 hours 
Alkaline 
48 hours 
Motility + + + 
Growth at 32°C + + + 
Sulfamethazine sensi­
tivity at 16 hours 
S5, 10, 20, 
30 mg./ml. 
S5, 10, 20, 
30 mg./ml. 
S5, 10, 20, 
30 mg./ml. 
Sensitivity to 0.02 
mg./ml. Furaltadone Sensitive Resistant Resistant 
Hemagglutination + 4- + 
24 hour blood agar 
culture HA titer 
256 16 16 
48 hour blood agar 
Culture HA titer 
8 8 2 
72 hour blood agar 
Culture HA titer 
2 4 2 
24 hour TPB 
Culture HA titer 
4 0 2 
24 hour blood agar 
Base culture HA titer 64 32 8 
48 hour blood agar 
Base culture HA titer 32 16 4 
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DISCUSSION 
In the past, the general approach to the control of infec­
tious atrophic rhinitis has been to reduce the exposure of young 
pigs to possible infectious agents and to institute measures to 
increase the resistance of the pig. With the recent documenta­
tion that Bordetella bronchiseptica is the principal cause of 
infectious atrophic rhinitis epizootics in major swine producing 
areas it becomes logical to focus control efforts on this spe­
cific organism. Bordetella rhinitis control by the detection 
and elimination of infected swine was shown in the present work 
to be a useful procedure in many herds for reducing the inci­
dence of B. bronchiseptica nasal infections and the elimination 
of clinical atrophic rhinitis. 
Table 1 indicates that on the first nasal swab culture 12 
percent of 3»304 breeding animals were culture-positive. The 
efficiency of B. bronchiseptica nasal infection detection in 
swine breeding stock by the nasal swab culturing procedure used 
in the present study was determined by compiling results 
obtained in 3 sequential samplings with the removal of 
culture-positive animals after each sampling. These results 
are presented in Table 1. It is apparent that 113 culture-
positive animals were detected on the second and third tests 
after being called culture-negative on the previous tests. 
When this number (113) of culture-positive animals is adjusted 
to reflect the decreased sample size, it becomes 201. This 
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indicates that a single nasal swab culture was capable of detect 
ing approximately 67 percent of the total number of infected 
animals detected by 3 samples. Of the 113 culture-positive 
animals detected on the second and third test, 40 escaped detec­
tion on the second test. If adjustment is made again for the 
decreased sample size then the second sampling had an efficiency 
of 62 percent. Assuming a 62 percent efficiency for the third 
sampling allows the determination that 3 nasal swab cultures 
have a detection accuracy of 9^.7 percent. 
Animals removed on the second and third nasal swab culture 
generally had lower culture plate B. bronchiseptica colony 
counts. Bordetella bronchiseptica may be present in such low 
numbers in these animals that it was beyond the detection abil­
ity of our sampling technique. 
It was recommended that all sows and gilts be sampled an 
additional time within 2 weeks prior to farrowing. By assum­
ing a 62 percent efficiency for the fourth sampling a 98.2 per­
cent detection accuracy can be predicted for 4 nasal swab 
cultures. 
A summary of the questionnaire response from 5^ veterinary 
practitioners participating in the Bordetella rhinitis control 
project indicated that there was clinical improvement in 79 per­
cent of those herds experiencing atrophic rhinitis epizootics 
to which the procedure was applied. This figure is considered 
to be highly significant considering the varying conditions 
under which the procedure was applied in the various herds. 
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Approximately 30,182 nasal swab samples from 152 herds 
were cultured in this laboratory in the course of the pilot 
field control project. One hundred and seven of the herds were 
culture-positive. A total of 76 of these isolates was tested 
for sulfamethazine resistance with 53 percent showing complete 
sulfamethazine resistance and 18 percent showing partial 
resistance. The rate of B. bronchiseptica isolation from all 
nasal swab specimens was found to be 11.6 percent. 
The nasal swab culturing procedure in 25 herds cultured at 
this laboratory was shown to be 77 percent efficient in elimi­
nating clinical atrophic rhinitis and 65 percent efficient in 
producing pigs that were culture-negative for B. bronchiseptica 
at weaning time. 
It was not possible in the present study to obtain detailed 
evaluations of the economic performance of swine herds before 
and after application of the nasal swab culture procedure, 
however, the owners of most of the severely affected herds 
reported that they were able to reestablish their swine produc­
tion on a profitable basis. 
These results indicate that the nasal swabbing procedure 
is an effective tool for the control of clinical Bordetella 
rhinitis in suitable swine herds. It can be used in certain 
herds to eradicate the organism entirely from the swine herd by 
continual nasal swab culturing pressure and strict herd health 
management practices. Possible reinfection from uncontrollable 
external sources makes eradication of B. bronchiseptica 
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difficult to achieve and maintain for long periods of time. 
Nasal swab culturing serves an additional function as a diagnos­
tic tool for the detection of B. bronchiseptica nasal infections 
in herds with and without clinical atrophic rhinitis. 
In Experiment II, it was found that 50 percent of the E. 
bronchiseptica isolates from the initially sulfamethazine resis­
tant infection had returned to complete or partial sensitivity 
within 2 months after removal of sulfamethazine medication. 
After 5 months without medication 100 percent of the infected 
pigs yielded isolates showing some degree of sulfamethazine 
sensitivity. 
The natural clearing rate observed in Experiment II was 
supplemented with field infection rate incidence observations 
by Switzer and Farrington (1972) to formulate an expected nat­
ural clearing rate of B. bronchiseptica from the nasal cavity 
of swine. Their predicted natural clearing rate is reproduced 
in Figure 17. 
The ability of swine to resist nasal infection by B. bron-
chiseptica with subsequent development of atrophic rhinitis 
probably involves several mechanisms. An age resistance to the 
development of turbinate atrophy occurs (Switzer, 1970b). Pigs 
infected after 3 to 5 weeks of life are expected to develop 
less severe lesions than those infected in the first 3 weeks of 
life. This is probably associated with the reduction in rate 
of tissue growth. Pigs infected after 8 to 10 weeks of age 
may develop inapparent infections and become carriers. 
Figure 17. Expected natural clearing rate of Bordetella bronchiseptica from the 
nasal cavity of swine. (Reproduced from Switzer, W. P. and D. 0. 
Farrington, 1972. J.A.V.M.A. l6l(ll)jl327.) 
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Harris and Switzer (1969) produced nasal and tracheal 
resistance against B. bronchiseptica reinfection in swine. 
They noted that swine freed from a virulent B, bronchiseptica 
infection by sulfonamide treatment or after natural clearing of 
low-virulence D-1 strain infection were extremely resistant to 
subsequent nasal challenge. Swine which had recovered from 
infection with D-1 strain were resistant to reinfection for up 
to 90 days post-nasal clearance. This resistance was not asso­
ciated with high serum agglutinating antibody titers. Resis­
tance was also not stimulated by intramuscular injection of a 
formalinized, whole-cell B strain B. bronchiseptica bacterin 
without adjuvant even though the bacterin induced high levels 
of circulating agglutinating antibody, Harris (1970) demon­
strated that almost all of a virulent challenge inoculum disap­
pears from the nasal cavities of D-1 strain cleared resistant 
swine in 2 to 6 hours after challenge while viable organisms 
were readily recovered from the nasal cavities of susceptible 
control animals. 
Accelerated nasal clearance of B, bronchiseptica was 
induced in 2-to-8-week-old swine by the subcutaneous adminis­
tration of a sonically disrupted and filtered D-1 strain vaccine 
and by a commercial pertussis vaccine^ (Harris and Switzer, 
1972), The bacterins were incorporated in equal amounts of 
Freund's incomplete adjuvant and injected in 2 ml, dosages 6 
^Eli Lilly and Company, Indianapolis, Indiana, 
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to 8 days apart. Twenty-seven of 30 vaccinated pigs were free 
from nasal infection approximately 6o days post-challenge while 
10 of 14 control pigs were still infected. They stated that 
the vaccines somehow stimulated recovery of the swine nasal 
cavity from B, bronchiseptica infection, but that this acceler­
ated recovery differed from the complete refractiveness against 
the challenge organisms shown by low-virulence strain D-1 
cleared resistant swine. 
Yoda et (1972) suggested that an immune state devel­
oped in guinea pigs infected with B. bronchiseptica. It was 
noted that infected guinea pigs usually recover within 20 weeks. 
Most guinea pigs were found to be in a highly resistant state 
after recovery from the natural infection and that this acquired 
resistance to nasal and tracheal infection lasted as long as 40 
weeks or more. Few of the recovered guinea pigs demonstrated a 
measurable agglutinin titer. Nikkels and Mullink (1971) con­
trolled B. bronchiseptica pneumonia outbreaks in an SPF guinea 
pig breeding colony by the use of an autogenous bacterin. They 
stated that a single dose of vaccine mixed with Preund's incom­
plete adjuvant not only controls losses due to pneumonia but 
may even eradicate the organism. 
Ross ^  ad. (1967) demonstrated that D-1 strain was regu­
larly eliminated from the swine nasal cavity by 6 to 7 weeks 
post-inoculation and was incapable of producing turbinate 
atrophy. Harris (1970) compared the phagocytosis of D-1 and 
B strain B. bronchiseptica by swine polymorphonuclear (PMN) 
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leucocytes. Strain D-1 was ingested by the leucocytes at a 
significantly higher rate than B strain. He stated the PMN 
leucocytes present in the nasal cavity of pigs may remove D-1 
strain infections more effectively than B strain infections 
and that this mechanism may be responsible for the more rapid 
natural clearance of D-1 strain. It was considered possible 
that the low-virulence strains were being phagocytized more 
rapidly than the virulent strains and that this reduction of 
the number of organisms present prevented the occurrence of 
turbinate atrophy. An increased rate of phagocytosis of B. 
bronchiseptica on the mucous surface may account for the 
increased clearance rate of nasal infection observed in pigs 
injected with a suitable B, bronchiseptica bacterin. 
The mechanism of the local resistance of the nasal cavity 
of swine cleared from B. bronchiseptica infection is apparently 
different than the previous defense system. Bordetella bronchi­
septica has been shown to attach to swine nasal epithelial cells 
(Harris, 1970). Holt (1972) reported that B. bronchiseptica 
adhered readily to live cultures of human fibroblasts. Gibbons 
(1973) considered bacterial adherence the first prerequisite 
for the successful colonization of a mucosal surface and that 
attachment ability was a critical determinant of the virulence 
of a particular organism. One of the early tissue damages in 
the area of a B. bronchiseptica microcolony on ciliated epithe­
lium is the disruption of the cilia (Duncan and Ramsey, I965). 
This affords a B. bronchiseptica microcolony an additional 
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defense against removal, Harris (1970) postulated that sub­
stances may be present in the respiratory tract secretions of 
pigs that may inhibit the attachment of B. bronchiseptica to 
nasal and tracheal epithelium. Such an inhibition of attach­
ment provides a mechanism that explains the resistance of the 
ciliated mucosa of the nasal cavity to B. bronchiseptica 
infection. This inhibition could be due to a blockage of the 
receptor sites on either the bacteria or the epithelial cells. 
Williams and Gibbons (1972), based on the information that SIgA 
mediates a local immune system, suggested that the mechanism of 
SIgA activity is the inhibition of bacterial adherence to mucous 
surfaces. The possible blockage of bacterial attachment sites 
by SIgA and other factors present in the nasal secretions of 
pigs with subsequent bacterial disposal by removal on the muco-
cilliary escalator, places the ciliated mucosal surface in 
perspective as the first line of immunological defense against 
B. bronchiseptica respiratory infections. 
Parenteral immunization of 4-to-8-week-old swine with 
whole-cell bacterins was examined in Experiment III. At 12 
weeks post-challenge 4 out of 13 (30 percent) experimental pigs 
receiving D-1 sonicate, whole-cell, D-1 whole-cell and 55 strain 
whole-cell bacterins with adjuvant were culture-positive for B, 
bronchiseptica while 6 out of 7 (86 percent) controls were cul­
ture -positive, This indicated that these whole-cell bacterins 
stimulated some degree of accelerated nasal clearance. The 
failure of the remaining bacterin to produce resistance to 
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infection or to significantly hasten nasal clearance may be 
related to production strain, lack of hemagglutinin content 
and/or the absence of an adjuvant. 
Experiment IV further evaluated the potential of D-1 soni­
cate, whole-cell bacterin with adjuvant as a parenteral immuniz­
ing agent in 3 and 6 week old pigs. At 2 weeks post-challenge 
4 out of 11 (36 percent) vaccinated pigs were culture-positive 
while 13 out of 13 (100 percent) of the controls were culture-
positive. This resistance waned in the vaccinated pigs until 
at 8 weeks post-challenge 7 out of 11 (64 percent) were 
culture-positive. This waning of resistance is not consistent 
with the results observed in Experiment III, The 3-week-old 
immunized pigs failed to develop significant serum PAST titers. 
The 6-week-old pigs receiving the nonadjuvanted bacterin also 
failed to maintain a high serum PAST titer for the duration of 
the experiment. This failure to obtain consistent high PAST 
serum titers may account for the loss of resistance observed in 
this trial. 
In Experiment V an attempt was made to clear virulent B 
strain infection from the nasal cavity of swine by the admin­
istration of D-1 sonicate, whole-cell bacterin without (1st 
dose) and with (2nd dose) adjuvant. This attempt was not 
successful. The infected immunized pigs cleared at about the 
same rate as the control pigs. This is consistent with the 
results of Harris and Switzer (1972). 
The pigs in Experiment VI were challenged with B strain 
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B. bronchiseptica at a 2 week midpoint between doses of D-1 son­
icate bacterin with AB-65 adjuvant. Accelerated nasal clearance 
of B. bronchise-ptica was induced as all pigs had cleared the 
nasal infection by 9-12 weeks. The average PAST serum titer at 
the termination of the trial was 1201. All 7 pigs had grossly 
normal turbinates at necropsy. 
In experiments III, IV and VI certain of the parenteral 
bacterins have shown sorae degree of accelerated nasal clearance 
of B. bronchiseptica nasal infections and have deterred gross 
turbinate atrophy. All pigs (28 of 28) immunized with D-1 son­
icate, whole-cell bacterin with adjuvant prior to nasal chal­
lenge had grossly normal turbinates while 2? percent (4 of 15) 
of the nonimmunized controls had gross turbinate atrophy. 
Holt (1972) stated the current practice of vaccinating 
infants subcutaneously with Bordetella pertussis vaccines may 
induce a therapeutic immunity and not a prophylactic immunity; 
that is, such vaccination may not protect against infection, 
but does protect against deeper tissue injury. This also 
appears to be the case with the D-1 sonicate, whole-cell bac­
terin with adjuvant failing to protect pigs against infection, 
but providing protection against deeper tissue damage (turbi­
nate atrophy). 
Intranasal immunization of 4-to-8-week-old pigs was evalu­
ated in Experiment VII. Live, low-virulence 55 strain B. bron-
chiseptica TPB culture was instilled intranasally in pigs with 
subsequent B strain challenge. Strain 55 intranasal vaccination 
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prevented the establishment of a swine virulent B strain B. bron-
chiseptica nasal infection with no evidence of a persistent 55 
strain infection. Intranasal immunization was reevaluated in 
Experiment VIII using 3-to-4-week-old pigs. Live, low-virulence 
strain 55 TPS culture intranasal vaccination again prevented the 
establishment of a swine virulent B strain B, bronchiseptica 
nasal infection. Sterile filtrates from 55 strain B, bronchi-
septica 24 hour TPB cultures did not prevent the initial estab­
lishment of a B. bronchiseptica nasal infection, but by 6 weeks 
post-challenge 5 of 6 pigs were cleared from the infection. 
Live, low-virulence 55 strain intranasally vaccinated pigs were 
challenged twice more at 8 and 1? weeks post-intranasal immuni­
zation with no evidence of a B. bronchiseptica nasal infection. 
These results establish that live, low-virulence 55 strain 
intranasal vaccination of pigs 3 weeks of age or older prevented 
the establishment of virulent B strain B, bronchiseptica nasal 
infection following experimental challenge. 
Necropsy examination of the pigs from Experiments VII and 
VIII revealed that all (10 of 10) of the live, low-virulence 
55 strain intranasally immunized pigs had normal nasal cavities 
while 71 percent (5 of 7) of the control pigs had mild to severe 
gross turbinate atrophy. All of the pigs receiving the 55 
strain TPB culture sterile filtrate had grossly normal 
turbinates. Strain 55 B, bronchiseptica was not detected in 
the nasal cavity of intranasally immunized swine as early as 6 
days post-intranasal instillation of the vaccine. The 
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resistance developed against B. bronchiseptica nasal infections 
following intranasal immunization was not associated with sig­
nificant levels of circulating agglutinating antibody. 
Murray (1973) states that evidence now exists that there 
is a distinct immunological system at the mucous surfaces of 
most species and that this system plays a major protective role 
in host resistance. The major secretory and protective antibody 
found on the mucous surfaces is IIS IgA, The site and nature of 
the local immune response is influenced by a number of factors 
including the route of administration of antigen, the quantity 
and persistence of antigen at the mucosal surface, the method 
of presentation of the antigen, and the type of antigen used, 
eg., live or dead. Live antigen was said to have a major 
advantage as live organisms may multiply and persist for long 
periods thereby producing higher and longer lasting levels of 
local antibody. Murray (1973) further states that immunization 
of local mucous surfaces has many disadvantages such as problems 
in adequate delivery of the antigen. Ogra and Karzon (1969) 
demonstrated that the output of SIgA antibody from mucosal sur­
faces is anatomically restricted to the site where antigen stim­
ulation has occurred and that there is no good evidence of immu-
logical memory at mucous surfaces as demonstrated by a secondary 
response. Nash and Holle (1973) did observe some evidence of a 
local memory effect. Murray (1973) recommended that for the 
optimum immunization of local mucous surfaces maximum dissemi­
nation of antigen to all parts of the system should be 
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accomplished and that immunological memory should be stimulated 
by systemic means. Live antigens, especially viruses, can ful­
fill both criteria following application at the mucous surface, 
but inactivated antigens may require a parenteral route of immu­
nization as well in order to ensure the development of an immu­
nological memory. 
In experiments IX and X the potential of immunizing baby 
pigs with live 55 strain intranasal vaccine was explored. In 
Experiment IX the 55 strain intranasal vaccine appeared to pro­
tect pigs nursing a nonimmunized sow from turbinate atrophy 
even though a B. bronchiseptica nasal infection became 
established. Intranasally vaccinated pigs nursing an immunized 
sow withstood establishment of a B. bronchiseptica nasal infec­
tion better than the pigs not receiving colostral antibody. 
The results of experiment X indicate the followingi 
(1) The use of AB-65 adjuvant in the bacterin produced a high 
titer in only 2 of the 3 immunized gilts. (2) The PAST serum 
titers in pigs nursing these immunized gilts was lower than 
that obtained in the pigs nursing the immunized sows in Exper­
iment IX. (3) The administration of live, low-virulence 55 
strain intranasal vaccine at 2 to 3 days of age with or without 
a booster dose at 21 or 35 days resulted in a reduction of 
nasal infection following B strain challenge. Forty-three per­
cent of the nasal swab cultures obtained from the intranasally 
immunized pigs nursing immunized gilts and 21 percent of those 
obtained from intranasally immunized pigs nursing nonimmunized 
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gilts were culture-positive. The figures were 83 percent and 89 
percent respectively for the nonimmunized control pigs. Five of 
6 intranasally vaccinated groups manifested resistance to B. 
"bronchiseptica nasal infection through 14 weeks post-challenge. 
The resistance of pigs nursing gilt 1 (immunized) and intra­
nasally vaccinated at 2, 3 and 21 days diminished between the 
10th and I4th week samplings. (4) Nonintranasally vaccinated 
pigs nursing gilt 3 (immunized) were infected at about the same 
rate as nonintranasally vaccinated pigs nursing gilt 4 
(nonimmunized) but the 2 groups of pigs developed a different 
degree of turbinate atrophy. One of 4 pigs nursing gilt 3 had 
moderate gross ventral turbinate atrophy at necropsy while 2 of 
3 pigs nursing gilt 4 had severe (almost complete absence of 
nasal turbinates) turbinate atrophy. (5) Thirty-two of 33 
(97 percent) intranasally immunized pigs nursing either immu­
nized or nonimmunized gilts were protected against turbinate 
atrophy, while 3 of 7 (43 percent) of the pigs not intranasally 
immunized but nursing either immunized or nonimmunized gilts 
developed gross turbinate atrophy. (6) Pigs nursing gilt 6 
(nonimmunized) that were intranasally immunized at 2, 3 and 35 
days and challenged with B strain at 45 days was a successful 
third demonstration that intranasal immunization of 4-to-7-week-
old pigs farrowed by nonimmunized dams (Experiments VII and VIII) 
were resistant to the establishment of B. bronchiseptica nasal 
infection for up to 12 weeks post-intranasal immunization. 
(7) No signs of clinical atrophic rhinitis were observed at any 
Iks 
time in any of the 55 strain B. bronchiseptica intranasally vac­
cinated groups of pigs. Clinical signs were observed in two of 
the seven nonintranasally vaccinated control pigs, 
A summation of the results obtained from intranasally vac­
cinated pigs in Experiments IX and X indicates that pigs nurs­
ing immunized dams had 30 percent (35 of 115) positive cultures, 
while pigs nursing nonimmunized dams had 34 percent (36 of 10?) 
positive cultures. It appears that the immune state of the dam 
did not affect either the incidence of infection or the develop­
ment of turbinate atrophy in intranasally immunized pigs. 
However, immunization of the dam did reduce the incidence and 
severity of turbinate atrophy if the pigs were not intranasally 
immunized. In Experiments IX and X intranasally immunized baby 
pigs nursing immunized dams had a zero percent (0 of 16) inci­
dence of gross turbinate atrophy while intranasally immunized 
baby pigs nursing nonimmunized dams had a 4 percent (1 of 26) 
incidence of gross turbinate atrophy. The nonintranasally 
immunized controls in Experiment X had an incidence of 25 per­
cent (1 of 4) and 67 percent (2 of 3) respectively 
Live, low-virulence 55 strain intranasal vaccination 
appears to have protected pigs from turbinate atrophy caused by 
B. bronchiseptica even though some of the pigs did become 
infected. This is indicated by the fact that pigs of all ages 
in Experiments VII, VIII, IX and X that were intranasally vac­
cinated with live, low-virulence 55 strain TPB culture had an 
incidence of gross turbinate atrophy of less than 2 percent 
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(1 of 52) while the controls from these experiments had an 
incidence of 57 percent (8 of 14). 
Smith (1972) reported that the resistance of newborn pigs 
to infectious atrophic rhinitis can be raised by breeding from 
older sows, restricting the intake of gilts into the breeding 
herd, mixing replacement gilts with older pigs before and dur­
ing pregnancy, selecting strains with inherent resistance and 
by immunization of the dams. Passively acquired maternal anti­
bodies were pictured as being an important factor in the over­
all resistance of a newborn pig to atrophic rhinitis. 
Kemeny (1973) found that pigs reared without colostrum 
developed turbinate atrophy more frequently than pigs fed either 
immune or nonimmune colostrum. He noted that parenteral immu­
nization induced much higher agglutination titers in the serum 
of dams than did colonization of the respiratory tract with 
live B. bronchiseptica organisms. Parenterally vaccinated gilts 
also had a much higher titer of antibody in their colostrum 
after parturition. 
There is presently no evidence to indicate the persistence 
in or transfer between swine of 55 strain b. bronchiseptica. 
In the absence of demonstrable swine to swine transfer for the 
determination of potential increased virulence of 55 strain the 
organism was back passaged through 11 passages in 6-to-8-day 
old embryonating hens eggs and introduced into the nasal cavity 
of susceptible 3-week-old pigs in Experiment XI, Strain 55 
b. bronchiseptica killed 100 percent of the embryos by 72 hours 
14? 
in the first passage. Swine virulent B strain B, bronchiseptica 
regularly kills 100 percent of 6-to-8-day-old chicken embryos by 
24 hours post-yolk sac inoculation. An increase in the virulence 
(earlier mortality) of 55 strain for chicken embryos was not evi­
denced through 11 serial passages. 
Strain 55 eleventh passage egg yolk inoculum was not 
detected in the nasal secretions of the intranasally inoculated 
pigs at 1 or 2 weeks post-inoculation. Swine receiving the 55 
strain eleventh egg passage inoculum were not completely refrac­
tory to subsequent B strain B. bronchiseptica nasal challenge 
but cleared the nasal infection by 5 weeks post-challenge. This 
may indicate that the serial embryonated hens egg passage 
reduced the antigenicity of the 55 strain B. bronchiseptica. 
Electron microscopic examination of 55 and B strain Borde-
tella bronchiseptica revealed that morphologically they closely 
resembled another strain of B. bronchiseptica (R-21) described 
by Richter and Kress (196?). Strain 55 and B strain individual 
coccobacillary cells varied in size from 0.4 by 0.72 to 0.6 x 
1.0 micrometers. The nuclear zones of B. bronchiseptica were 
quite distinct and consist of whorls or of a network of fibrils 
and dense bodies. The convoluted surface was typical of gram-
negative bacteria, the cell wall was composed of 5 layers, the 
flagella had a multistranded appearance and nucleoidal material 
consisted of fibrils and dense bodies. 
Strain 55 and B strain organisms were morphologically 
similar. Fibrillar appendages were more numerous on the B 
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strain organisms. Individual 55 strain cells may have large 
numbers of these appendages but on the average they were quanti­
tatively fewer in 55 strain 24 hour blood agar cultures, Morse 
and Morse (1970) in discussing the biological properties of 
filamentous particles found in the supernatant fluids of phase 
I Bordete11a pertussis cultures stated that induction of lympho­
cytosis and histamine-sensitizing activity was associated only 
with those gradient fractions in which these filaments were 
found. The degree of lymphocytosis and histamine-sensitizing 
activity paralleled the concentration of the filaments in the 
preparation. Bordetella bronchiseptica does not have lymphocy­
tosis promoting activity (Morse and Morse, 1970). 
The cellular protrusions of unknown significance encoun­
tered in a negatively stained 48 hour TPS culture of 55 strain 
were not observed in similar preparations of B strain. This may 
be a morphologically unique structure in strain 55. The exact 
origin of the circular protrusion was not ascertained. 
The colony morphology of 55 strain on modified MacConkey's 
agar medium without Furaltadone was modified as compared to D-1 
and B strains. However, due to the wide variation in colony 
morphology and rapid phase variations observed with B. bronchi-
sept ica isolates, depending on the cultural environment, colony 
morphology is not a satisfactory criteria for strain 
differentiation. 
Motility was absent in some 55 strain cultures while D-1 
and B strain organisms were uniformly motile. Strain 55 was 
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sensitive to the 0.02 mg./ml. Furaltadone concentration in mod­
ified MacConkey's agar medium. This is significant as it allows 
a discrimination to be made between 55 strain and most other 
known B, bronchiseptica isolates. 
Strain 55 gives a weak and slow positive reaction in 
Simmon's citrate agar. This may be a matter of cell concentra­
tions in the inoculum and/or growth inhibition. 
Strain 55 had the highest hemagglutination titer among the 
three strains. Harris (1970) determined that 48 hour blood 
agar cultures of D-1 and B strain B. bronchiseptica had HA 
titers of 128 and 64 respectively. He found a decrease in HA 
titer in both D-1 and B strains on continued passage on artifi­
cial medium. The hemagglutinating ability of B, bronchiseptica 
isolates does not appear to be a characteristic associated with 
virulence for swine as both 55 and D-1 strains are more potent 
hemagglutinating organisms than swine virulent B strain. The 
hemagglutination titers were reduced by increased time of incu­
bation on the blood agar and tryptose blood agar base (without 
blood) media. 
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SUMMARY 
Bordetella bronchiseptica rhinitis control in swine breed­
ing herds by culturing of 3 nasal swabs from each animal with 
subsequent elimination of culture-positive animals was 
evaluated. A total of 30,182 nasal swab samples from 152 swine 
herds were cultured. Bordetella bronchiseptica nasal infection 
detection by 3 nasal swab cultures was determined to be 94.7 
percent accurate. Response from 5^ veterinary practitioners 
participating in the Bordetella rhinitis control project indi­
cated there was a reduction in clinical atrophic rhinitis in 79 
percent of those herds utilizing the procedure. Thirteen of 17 
(77 percent) herds cultured by this laboratory eliminated clini­
cal atrophic rhinitis and 15 of 23 (65 percent) produced pigs 
that were culture-negative for B. bronchiseptica at weaning age. 
Bordetella bronchiseptica isolates from 76 herds were tested 
for sulfamethazine resistance. Fifty-three percent were resis­
tant, 18 percent had partial resistance and 29 percent were 
sulfamethazine sensitive. 
A group of pigs infected with a B. bronchiseptica isolate 
that was sulfamethazine resistant, yielded B. bronchiseptica 
with some degree of sulfamethazine sensitivity after the pigs 
had been removed from the drug for 5 months. 
Four of 13 (30 percent) 4-to-8-week-old pigs parenterally 
immunized with B. bronchiseptica whole-cell bacterins with 
adjuvant were culture-positive for B. bronchiseptica 12 weeks 
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post-challenge while 6 of 7 (86 percent) controls were culture-
positive. At 2 weeks post-challenge 4 of 11 (36 percent) 3-to-
6-week-old pigs parenterally immunized with sonicated, whole-
cell bacterin with adjuvant were culture-positive for B, bron-
chiseptica while 13 of 13 (100 percent) of the controls were 
culture-positive. Resistance waned in this group of pigs. At 
8 weeks post-challenge 7 of 11 (64 percent) were culture-
positive. In 4 trials, all pigs (28 of 28) immunized with son­
icated, whole-cell bacterin with adjuvant prior to nasal chal­
lenge had grossly normal turbinates while 27 percent (4 of I5) 
of the nonimmunized controls had gross turbinate atrophy. 
Live, low-virulence 55 strain intranasal vaccination of 
pigs 3 weeks or older prevented the establishment of virulent 
B. bronchiseptica nasal infection following experimental chal­
lenge with no evidence of a persistent 55 strain nasal infection. 
Gross necropsy examination of the intranasally vaccinated pigs 
revealed that all (10 of 10) of the pigs had normal nasal cavi­
ties while 71 percent (5 of 7) of the nonintranasally vaccinated 
control pigs had mild to severe turbinate atrophy. 
Intranasally vaccinated baby pigs that nursed immunized 
dams had 30 percent (35 of 115) positive cultures while 34 per­
cent (36 of 107) of the pigs nursing nonimmunized dams had 
positive cultures. Some of these pigs were subjected to con­
stant exposure to the infected control pigs. Intranasally vac­
cinated baby pigs nursing immunized dams had a zero incidence 
(0 of 16) of gross turbinate atrophy at necropsy while intra­
nasally vaccinated baby pigs nursing nonimmunized dams had a 
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4 percent (1 of 26) incidence. The nonintranasally immunized 
controls had an incidence of 25 percent (1 of 4) and 6? percent 
(2 of 3) respectively. It appears that the immune state of the 
dam did not affect either the incidence of infection or the 
development of turbinate atrophy in intranasally immunized pigs. 
However, immunization of the dam did reduce the incidence and 
severity of turbinate atrophy if the pigs were not intranasally 
immunized. 
Live, low-virulence 55 strain intranasally vaccinated pigs 
appear to have been protected against turbinate atrophy caused 
by virulent B. bronchiseptica even though some of the pigs did 
become infected. Pigs of all ages that were intranasally vacci­
nated with live, low-virulence 55 strain TPB culture had an 
incidence of gross turbinate atrophy of less than 2 percent 
(1 of 52) while the control pigs had an incidence of 57 percent 
(8 of 14). The 55 strain B. bronchiseptica isolate was not 
detected on nasal swab culture 6 days post-vaccination. 
Electron microscopic examination of the 55 strain immuniz­
ing and the B strain virulent challenge B. bronchiseptica 
revealed that they both closely resembled previously described 
B. bronchiseptica. 
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